 
 Protocol with Statistical Analysis Plan Cover Page:   
 
Official Title:  A Study to Evaluate the Effects of fixed dose Flavonoid Isoquercetin on 
thrombo -inflammatory biomarkers in subjects with stable Sickle Cell Disease 
NCT number:   [STUDY_ID_REMOVED] 
Document Type:   Protocol  
Document Date:  05/05/2023  
 
 
1 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 Abbreviated Title: IQ in sickle cell disease  
Protocol : 20H0137 
Version Date:  May 5 , 2023 
 
Title: A Study to Evaluate the Effects of fixed dose Flavonoid Isoquercetin on thrombo-
inflammatory biomarkers in subjects with stable Sickle Cell Disease  
 
NIH Principal Investigator:  Arun S. Shet, MD, Ph.D. 
Sickle Cell  Branch , NHLBI  
Building 10- CRC, Rm 6N240B 
10 Center Dr , 
Bethesda, MD 20892 
Phone: 301-827-6808 E-mail: arun.shet@nih.gov 
 
Investigational Agents:  
Drug Name:  Isoquercetin 
IND Number:  150896 
Sponsor: NHLBI  
Manufacturer:  Querces AG  
 
   
2 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 TABLE OF CONTENTS  
TABLE OF CONTENTS  ................................................................................................................ 2  
STATEMENT OF COMPLIANCE  ................................................................................................ 6  
1 PROTOCOL SUMMARY  ............................................................................................... 7  
1.1 Synopsis ........................................................................................................................... 7  
1.2 Schema  ............................................................................................................................. 9  
1.3 Schedule of Activities (SOA) ......................................................................................... 10  
2  INTRODUCTION  ......................................................................................................... 11  
2.1 Study Rationale .............................................................................................................. 11  
2.2 Background .................................................................................................................... 12  
Sickle Cell Disease  ............................................................................................................... 12  
Epidemiology of Venous Thromboembolism in Sickle Cell Disease .................................. 13  
Sickle Erythrocytes, Endothelial Inflammation and Thrombosis  ......................................... 14  
Tissue Factor, hypercoagulability and thrombosis in SCD .................................................. 15  
Endothelial – Leukocyte – Platelet mediated inflammation in SCD  .................................... 17  
Regulatory control of Tissue Factor ..................................................................................... 18  
Vascular Protein Disulfide Isomerase: thrombosis and tissue factor regulation  .................. 19  
Isoquercetin inhibits PDI and lowers P- selectin  ................................................................... 20  
2.3 Risk/Benefit Assessment  ................................................................................................ 22  
2.3.1 Known Potential Risks ................................................................................................. 22  
2.3.2  Known Potential Benefits  ....................................................................................... 24  
2.3.3  Assessment of Potential Risks and Benefits  ........................................................... 24  
3 OBJECTIVES AND ENDPOINTS  ...................................................................................... 25  
4 STUDY DESIGN .................................................................................................................. 26  
4.1 Overall Design  ................................................................................................................ 26  
4.2 Scientific Rationale for Study Design  ............................................................................ 27  
4.3 Justification for Dose  ..................................................................................................... 27  
5 STUDY POPULATION  ....................................................................................................... 28  
5.1 Inclusion Criteria  ............................................................................................................ 28  
5.2 Exclusion Criteria  ........................................................................................................... 28  
5.3 Inclusion of Vulnerable Participants  .............................................................................. 29  
5.4 Lifestyle Considerations  ................................................................................................. 29  
3 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 5.5 Screen Failures  ............................................................................................................... 30  
5.6 Strategies for Recruitment and Retention  ...................................................................... 30  
5.6.1  Costs  ........................................................................................................................ 30  
5.6.2  Compensation ......................................................................................................... 30  
6 STUDY INTERVENTION  ................................................................................................... 31  
6.1 Study Interventions(s) Administration  ........................................................................... 31  
6.1.1  Study Intervention Description ............................................................................... 31  
6.1.2  Dosing and Administration ..................................................................................... 32  
6.1.3  Dose Escalation  ....................................................................................................... 32  
6.1.4  Dose Limiting Toxicity  ........................................................................................... 32  
6.1.5  Dose Modifications  ................................................................................................. 32  
6.1.6  Drug Administration  ............................................................................................... 32  
6.2 Preparation/Handling/Storage/Accountability  ............................................................... 32  
6.2.1  Acquisition and Accountability  .............................................................................. 32  
6.2.2  Formulation, Appearance, Packaging, and Labeling .............................................. 32  
6.2.3  Product Storage and Stability.................................................................................. 33  
6.2.4  Preparation  .............................................................................................................. 33  
6.3 Measures to Minimize Bias: Randomization and Blinding  ........................................... 33  
6.4 Study Intervention Adherence ........................................................................................ 33  
6.5 Concomitant Therapy ..................................................................................................... 33  
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ..................................................................................... 34  
7.1 Discontinuation of Study Intervention ........................................................................... 34  
7.2 Participant Discontinuation/Withdrawal from the Study  ............................................... 34  
7.3 Lost to Follow-up ........................................................................................................... 35  
8 STUDY ASSESSMENTS AND PROCEDURES  ................................................................ 35  
8.1 Screening Procedures ..................................................................................................... 35  
8.2 Study evaluation Procecures .......................................................................................... 36  
8.2.2  Biospecimen Evaluations ........................................................................................ 38  
8.2.3  Correlative Studies for Research/Pharmacokinetic Studies  .................................... 40  
8.2.4  Samples for Genetic/Genomic Analysis  ................................................................. 40  
8.3 Safety and Other Assessments  ....................................................................................... 41  
4 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 8.4 Adverse Events and Serious Adverse Events ................................................................. 41  
8.4.1  Definition of Adverse Event ................................................................................... 41  
8.4.2  Definition of Serious Adverse Events (SAE) ......................................................... 41  
8.4.3  Classification of an Adverse Event  ......................................................................... 41  
8.4.4  Grading and attribution of adverse events .............................................................. 42  
8.4.5  Relationship to Study Intervention ......................................................................... 42  
8.4.6  Expectedness ........................................................................................................... 43  
8.4.7  Time Period and Frequency for Event Assessment and Follow- Up ....................... 43  
8.4.8  Adverse Event Reporting ........................................................................................ 44  
8.4.9  Serious Adverse Event Reporting ........................................................................... 44  
8.4.10  Events of Special Interest ........................................................................................ 45  
8.4.11  Reporting of Pregnancy .......................................................................................... 45  
8.5 Unanticipated Problems  ................................................................................................. 45  
8.5.1  Definition of Unanticipated Problems (UP) ........................................................... 45  
8.5.2  Unanticipated Problem Reporting  ........................................................................... 46  
8.5.3  NIH Intramural IRB Reporting of IND Safety Reports  .......................................... 46  
9 STATISTICAL CONSIDERATIONS.................................................................................. 46  
9.1 Statistical Hypothesis  ..................................................................................................... 46  
9.2 Sample Size Determination  ............................................................................................ 46  
9.3 Populations for Analyses  ................................................................................................ 47  
9.3.1  Evaluable for toxicity  .............................................................................................. 47  
9.3.2  Evaluable for objective response  ............................................................................ 47  
9.4 Statistical Analyses  ........................................................................................................ 47  
9.4.1  General Approach  ................................................................................................... 47  
9.4.2  Analysis of the Primary Endpoints  ......................................................................... 47  
9.4.3  Analysis of the Secondary Endpoint(s) ................................................................... 48  
9.4.4  Safety Analyses  ....................................................................................................... 48  
9.4.5  Baseline Descriptive Statistics  ................................................................................ 50  
10 REGULATORY AND OPERATIONAL CONSIDERATIONS  ......................................... 50  
10.1  Informed Consent Process .............................................................................................. 50  
10.1.1  Consent/Assent Procedures and Documentation .................................................... 50  
10.1.2  Consent for minors when they reach the age of majority  ....................................... 51  
5 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 10.1.3  Telephone consent .................................................................................................. 51  
10.1.4  Participation of Subjects who are/become Decisionally Impaired  ......................... 51  
10.2  Study Discontinuation and Closure ................................................................................ 51  
10.3  Confidentiality and Privacy ............................................................................................ 52  
10.4  Future use of Stored Specimens and Data ...................................................................... 52  
10.5  Safety Oversight ............................................................................................................. 53  
10.6  Clinical Monitoring  ........................................................................................................ 53  
10.7  Quality Assurance and Quality Control ......................................................................... 53  
10.8  Data Handling and Record Keeping ............................................................................... 54  
10.8.1  Data Collection and Management Responsibilities ................................................ 54  
10.8.2  Study Records Retention ......................................................................................... 54  
10.9  Protocol Deviations ........................................................................................................ 54  
10.10  Publication and Data Sharing Policy .............................................................................. 54  
10.10.1  Human Data Sharing Plan ....................................................................................... 54  
10.10.2  Genomic Data Sharing Plan .................................................................................... 55  
10.11  Collaborative Agreements  .............................................................................................. 55  
10.11.1  Agreement Type  ...................................................................................................... 55  
10.12  Conflict of Interest Policy  .............................................................................................. 55  
11 ABBREVIATIONS  .............................................................................................................. 55  
REFERENCES ............................................................................................................................. 58  
 
  
6 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 STATEMENT OF COMPLIANCE 
The trial will be carried out in accordance with International Conference on Harmoniz ation  Good 
Clinical Practice (ICH GCP) and the following:  
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 
CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 312)  
National Institutes of Health (NIH)- funded investigators and clinical trial site staff who are 
responsible for the conduct, management, or oversight of NIH- funded clinical trials have 
completed Human Subjects Protection and ICH GCP Training. 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the Institutional Review Board (IRB) for review and approval.  Approval of both the protocol and the consent form must be obtained before any participant is enrolled.  Any amendment to the protocol will require review and approval by the IRB before the changes are implemented to the study.  In addition, all changes to the consent form will be IRB-approved; a determination will be made regarding whether a new consent needs to be obtained from participants who provided consent, using a previously approved consent form. 
  
7 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019  
1 PROTOCOL  SUMMARY  
1.1 S YNOPSIS  
Title:  Study to Evaluate the Effects of fixed dose Flavonoid Isoquercetin on 
thrombo- inflammatory biomarkers in subjects with stable Sickle Cell 
Disease  
Study Description : Similar to cancer, sickle cell disease is associated with an acquired 
hypercoagulable state and exhibits a  high prevalence of incident and 
recurrent venous thromboembolism  (VTE) . Elevated levels of the 
procoagulant protein tissue factor and its activator, protein disulfide 
isomerase (PDI) in humans with sickle cell disease ( SCD) suggest a 
causal role for thrombo genesis. In cancer patients, pharmacological 
inhibition of plasma PDI with Isoquercetin (IQ) led to a reduction in 
VTE biomarkers and VTE recurrence . These findings provide support 
to test the hypothesis that Isoquercetin in sickle cell disease  would 
diminish thrombo -inflammatory VTE biomarkers  and attenuate the 
associated hypercoagulable state.  
Objectives:  
 1) To measure the effect of Isoquercetin, an oral inhibitor of 
vascular  PDI, on plasma soluble P- selectin  levels in subjects with 
stable SCD. 
2) To assess the clinical safety and tolerability of 1000  mg IQ  in 
subjects with stable SCD.  
3) To determine the effect of IQ on markers of hypercoagulability  
(plasma PDI , circulating tissue factor positive extracellular 
vesicles, plasma tissue factor procoagulant activity and plasma 
thrombin generation ) in subjects with stable sickle cell disease.   
Endpoints:  The primary outcome will be the change in plasma soluble P -selectin 
level  comparing the baseline versus IQ  or placebo .  
Secondary outcomes are to: 
1) Compar e baseline and end of study plasma PDI  activity  
2) Compar e baseline and end of study plasma tissue factor positive 
extracellular vesicle  number 
3) Compar e baseline and end of study p lasma tissue factor 
procoagulant activity 
4) Compar e baseline and end of study inflammation and coagulation 
parameters  
5) Compare baseline and end of study contemporary biomarkers of 
vascular function and atherothrombosis 
6)  Assess safety /tolerability and adherence to oral IQ 
  
Study Population:  Up to 46 male and female subjects  of all races  between the ages of 
18-70 years with SCD  who live locally will be enrolled . 
8 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 Phase:  II  
Description of 
Sites/Facilities 
Enrolling 
Participants :                        Enrollment and study visits will take place at the NIH Clinical 
Center .                                                                                                         
Subjects with sickle cell disease  
Description of Study 
Intervention:  Isoquercetin  1000 mg or placebo once  daily by mouth  for 28 days.   
Study Duration:  2 years   
Participant 
Duration:  
    
 5-9 weeks  
     
 
  
9 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 1.2 S CHEMA  
 
 
 
  
 
           

10 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019  1.3 S CHEDULE OF ACTIVITIES (SOA)  
 
EVALUATION AND ASSESSMENTS  Screening (A)  Baseline  End of 
Study  Phone Call 
(B) 
PROTOCOL TIMEPOINT VISITS  1 2 3 4 
Days    D0 D28 D56 
Window +/ - days  -90Days -28Days  + 7Days  ± 7Days  
Evaluations & Consent          
Consent to study  x       
Review Inclusion/Exclusion Criteria  x x     
Review of Medical History  x x  x    
Procedures & Assessments          
Establish Baseline Symptoms    x     
Physical Examination  x x x   
Review of Medications  x x x   
Vital Signs with Weight (kg)  x x x   
Review Of Adverse Events    x x x 
24-hour Dietary Recall  x x x  
Peripheral Arterial Tonometry (PAT) (ENDO -PAT)    x 4 x 4   
NIRS (Near Infrared Spectometry)   x 4 x 4  
CHEMISTRY LABS          
Female, Pregnancy Test, Beta HCG  (blood or urine)  x1 x1 x1   
Acute Care Panel  x x x   
Mineral Panel  x x x   
Fasting Glucose  x       
Hepatic Panel  x x x   
Total Protein   x x x   
Creatinine Kinase   x x x   
Uric Acid   x x x   
C-Reactive Protein (hs -CRP)    x x   
B-type natriuretic peptide (P -BNP)    x x   
Lactate Dehydrogenase   x x x   
Calculated Creatinine Clearance   x x x   
Viral Serology: HIV, hepaititis B and C (Serum HBsAg, anti -HBc, anti -HBs, anti -HCV, anti -
HIV)  x       
HEMATOLOGY LABS          
CBC with differential  x x x   
Hemoglobin Electrophoresis  x x x   
D-Dimer  x x x   
Coagulation Screen (PT, PTT, INR, Fibrinogen)  x x x   
Reticulocyte Count  x x x   
Direct Antiglobulin Screen   x  x   
Research Samples (Up to 30 mL)          
Biochemical Studies ( 3 ml 3.8% Sodium Citrate)    x x   
Coagulation Studies ( 9 ml 3.8% Sodium Citrate)    x x   
Red Blood Cell Studies ( 6 ml EDTA tube)    x x   
Platelet Function Test ( 6 ml 3.8% Sodium Citrate)    x x   
11 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 Leukocytes isolation for gene expression and RNAseq ( 3 ml 3.8% Sodium Citrate)    x x   
Study Supplement Medication          
Study Supplement Randonization    x     
Study Supplement, Diary and Electronic Pill Dispenser Dispensed    x3     
Study Supplement Compliance      x2   
Study Supplement, Diary and Electronic Pill Dispenser Returned      x   
A =  Screening tests will be done at the Screening Visit unless any of the tests have been performed under another NIH protoc ol 
within 90 days prior to  day 0 of study drug. 
B. Any adverse event requiring a clinic visit during that safety follow up period will be managed as clinically indicated 
x1 = for females of child bearing potential  
x2 = subject must be greater than or equal to 75% to be considered compliant  
x3 = counsel subjects to maintain a stable diet and not start any new diet or active SCD  treatment for the duration of the study (Pill 
Dispenser is optional). x
4 = ENDO-PAT and NIRS testing are optional and completion will be based on availability of service and participant willingness.  
 
2  INTRODUCTION  
2.1 S TUDY RATIONALE  
Sickle C ell Disease (SCD)  and cancer are chronic conditions that share an acquired 
hypercoagulable state which clinically manifests as venous thromboembolic disease and 
contributes to mortality  1. Moreover, both disorders share a similar increased risk for bleeding 
upon exposure to short and long term anticoagulation, the standard treatment for venous thromboembolism 2
,3. Scientific evidence supports the notion that inflammation perturbs 
endothelial and leukocyte homeostasis and upregulat es tissue factor  (TF)  and P- selectin 
expression, two major contributors to thrombo -inflammatory pathobiology  in SCD 4-6. 
Endothelial and platelet injury in SCD also likely contributes  to elevated plasma protein disulfide 
isomerase ( PDI) levels possibly explain ing higher PDI concentrations on the surface of sickle 
RBCs compared to normal red blood cells ( RBCs ) 7. PDI, a vascular thiol isomerase released 
during endothelial/platelet injury stimulates thrombin production by generating platelet factor Va in humans, and upon vascular injury in mice, facilitates fibrin deposition 8-10. PDI mediates 
these effects through oxidation of the Cys 186-Cys 209 bond and allosteric activation of TF, 
which decrypts TF pro coagulant activity 11,12. Decryption of circulating TF pro coagulant 
activity by plasma PDI possibly explains TF driven activation of coagulation in SCD. 
Consequently, increased TF pro coagulant activity triggers activation of intravascular coagulation which combined with venous stasis/hypoxia provokes venous thromboembolism (VTE) .  
Si
nce SCD patients have increased blood borne tissue factor , sustained thrombin generation and 
demonstrate features of platelet activation , plasma PDI inhibition, by restoring post- translational  
regulatory control of TF, might attenuate the associated hypercoagulable state. Suc h an approach 
is rationalized by observations of elevated  plasma PDI activity SCD mice that when exposed to a 
pharmacologic PDI inhibitor demonstrate d reduced vaso -occlusive crisis and microvascular 
thrombosis 13. In a phase II trial of patients with active cancer , t he flavonoid Isoque rcetin  (IQ) 
(Querces AG, Switzerland)) robustly inhibit ed plasma PDI activity and favorably reduc ed 
soluble P- selectin , a biomarker predictive  of VTE  development 14. Besides, none of these 
patients experienced any increased risk of bleeding typically observed with  exposure to warfarin 
or non- vitamin K oral anticoagulants  2,3. The salutatory  benefits of lowering soluble P -selectin 
12 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 in SCD patients are both reduced inflammation and  TF expression. Therefore, our overall 
hypothesi s is that therapeutic intervention with IQ would lower soluble P- selectin and  
simultaneously decrease the prothrombotic effects of TF without a concomitant ly increased risk 
for bleeding. Evaluating the effects of  IQ-mediated PDI inhibition on blood borne TF 
procoagulant activity and plasma soluble P- selectin will provide important insight into the  
pathophysiologic basis of the hypercoagulable state in SCD.  
 
2.2 B ACKGROUND  
Sickle C ell Disease (SCD) is an inherited mo nogenic hemoglobin disorder caused by a mutation 
in the gene encoding the β globin subunit of adult hemoglobin (HbA) resulting in a substitution 
of valine for glutamic acid at position 6 and thus producing hemoglobin S (HbS) 15. When 
deoxygenated, HbS polymerizes, rendering the red cell rigid, viscous, and abnormally adherent 
to the capillary endothelium. This impedes blood flow in the microcirculation, causing ischemia and microinfarcts that lead to painful crises, cerebrovascular stroke, renal impairment, retinopathy and other end-organ damage. The current scientific literature currently recognizes the 
contribution of an acquired hypercoagulable state in SCD to vascular pathobiology, chronic organ dysfunction, and mortality. 
Sickle Cell Disease  
A
lthough sickling disorders occur predominantly in individuals of African descent, the disease is 
truly global with prevalen ce in the Mediterranean, Middle East, parts of India, the Caribbean, 
and South and Central America 16. Worldwide, it is estimated that more than 300,000 children 
are born with SCD each year 16. However, due to population migration, t he clinical management 
of SCD is now routine medical practice in the United States 17,18. In the US, SCD affects an 
estimated 100,000 Americans (the vast majority of whom report African descent), and about one 
in 365 African-American newborns 19. An additional three million individuals heterozygous for 
the rs334 mutation (Hb AS) possess the sickle cell trait  (SCT) 20.  
Frequent attacks of vaso -occlusive crises (VOC), chronic pain, and end organ damage result in 
recurrent hospitalization, morbidity and increased health system utilization 21. Premature 
mortality in SCD is also high, with an age of death estimated to be 33.4 year s for SCD males and 
36.9 years for SCD females in 2005 20, owing largely to an incompletely characterized small 
and large vessel “vasculopathy” that affects the heart, lungs, liver, and kidneys 22. Amongst 
clinical presentations accounting for mortality are  severe VOC, acute chest syndrome ( ACS), 
pulmonary hypertension (PH), VTE,  asthma, and  heart failure  23-27. Approximately 10% of 
SCD patients have PH, which puts them at a higher two year mortality compared to SCD patients 
without PH 28-30. A variable proportion of these patients have chronic thromboembolic 
pulmonary hypertension (CTEPH) as the primary causative factor of their PH 30. SCD patients 
have a 12% cumulative incidence of VTE, either deep venous thrombosis (DVT) or pulmonary 
embolism (PE), putting them at a 2 – 3 fold higher mortality compared to patients without VTE 
26,31. Associated pulmonary thrombosis is observed in up to 20% cases of ACS, the latter being 
associated with high mortality 32.  
13 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 Widespread  clinical use of disease modifying therapies such as prophylactic antibiotics in 
children, hydroxyurea to increase fetal hemoglobin,  and simple blood transfusion, coupled with 
greater acceptance of stem cell  transplantation , have led to improved patient survival over the 
past two  decades 33-35. As a consequence, there is a growing population of older adults with 
SCD likely to be exposed to age related increased VTE risk 36,37, in addition to the already high 
risk of VTE in these patients related to their underlying SCD. Even individuals with 
heterozygous SCT appear t o have a higher risk for VTE, specifically pulmonary thrombosis 
38,39. Since African Americans have a higher risk for VTE compared to other ethnic groups in 
the US 40, it remains to be determined whether this increased risk is solely attributable to HbS. 
Increased VTE among SCD patients and among individuals with SCT makes studies of venous 
thrombosis a clinical research priority.  
Epidemiology of Venous Thromboembolism in Sickle Cell Disease 
The clinical course of SCD is highly variabl e  yet inexorable vascular organ dysfunction 
stemming from chronic vasculopathy is a hallmark of disease and eventually occurs in most SCD 
patients . Chronic hemolysis and recurrent vaso -o cclusive crises resulting in tissue damage likely 
play a causal role. The d amage inflicted to the vasculature by pathological adherence of sickle 
red cells provokes inflammation, vasoconstriction, oxidative damage, and a prothrombotic state . 
Vasculopathy is therefore a key driver of many of the organ complications of SCD.  
Thrombotic arterial vasc ulopathy is historically well recognized in SCD particularly in the 
context of stroke 41,42, but an appreciation of the role of thrombotic venous vasculopathy in 
SCD is more recent 1,43. Clinically, this is manifest as high cumulative VTE incidence ~12% by 
age 40 which is substantially earlier than in the general population. The more severe genotypes 
(HbSS and HbS β0) and/or patients hospitalized > 3 times a year with a pain crisis are at greatest 
risk. Short and long term VTE complications include higher mortality, chronic thromboembolic pulmonary hypertension, post phlebitic syndrome, and venous leg ulceration and increased mortality 44
,45. ACS has been shown to be coincident with pulmonary venous thrombosis in up 
to 20% cases, prompting exploration of the the rapeutic benefits of heparin ( [STUDY_ID_REMOVED]) 
32,46. VTE incidence is 3 fold higher even among 15-30 year young SCD patients, comparable 
to the excess thrombosis risk in carriers of the Factor V Leiden mutation, a well-studied inherited prothrombotic state with an increased risk for early VTE 31. The frequent incidence and 
recurrence of VTE in SCD patients 2,26,31 suggests a “high risk” prothrombotic state similar in 
risk to that associated with a ctive cancer 1,47.  
Current consensus recommendations from large clinical trials following  a first episode of VTE in 
the general population support anticoagulation treatment for  a minimum of 3 months 48. The risk 
of VTE recurrence following the discontinuation of anticoagulation, is well recognized  45. 
Owing to the complex risk/benefit ratio based on weighing the risk of increased bleeding versus recurrent thromboembolism, e xtension of anticoagulation beyond the 3-month period in a patient 
with first VTE is individualized. Amongst individuals with un provoked VTE or in those with a 
known hypercoagulable state such as active cancer, the consensus is to extend the duration of anticoagulation indefinitely 49. Notably, SCD patients were largely excluded from studies that 
led to these conclusions. T here is a lack of robust, externally validated VTE recurrence and/or 
bleeding scores that might help guide  long- term treatment decisions in SCD 1,43,48,49. The high 
cumulative incidence of recurrent VTE in SCD (14% at 1 year and over 25 % at 5 years) provide 
14 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 a strong clinical rationale for extended duration anticoagulation as secondary prophylaxis 2. 
However, the exact duration for which anticoagulation must be extended is uncertain and the 
increased risk of bleeding noted in SCD patients while on anticoagulation warrants caution 2. 
Yet, in the absence of robust evidence, following an initial episode of VTE, indefinitely extended anticoagulation remains a practical choice for many SCD patients and their physicians 1.  
There is widespread evidence for coagulation system activation is SCD patients both during VOC and between VOC, while in their usual st ate of health, i.e., in “ steady state” 1. Correlating 
these biomarkers with clinical evidence for VTE suggests a distinct overlap between SCD and inherited prothrombotic states such as Factor V Leiden. Unfortunately, the absence of clinical or laboratory tests predictive of VTE incidence/recurrence coupled with a higher than average bleeding risk in SCD associated with exposure to traditional ant icoagulants like warfarin or 
agents that target factor X and factor II presents challenges. Novel therapies providing  
antithrombotic  effects without increasing the risk of bleeding are therefore highly desirable. As 
an example, targeting coagulation factors XI to prevent surgically -provoked VTE in the general 
population is as efficacious as heparin but is associated with a lower risk of bleeding 50. 
Targeting thrombo- inflammatory pathways, that are disproportionately activated in SCD patients 
for e.g., the TF pathway, are highly relevant from this perspective.  
Sickle Erythrocytes, Endothelial Inflammation and Thrombosis 
Hb-S
 polymerization, hemolytic anemia, and impaired microcirculatory blood flow from acute 
vaso-occlusion are central to SCD pathophysiology 51,52. The primary pathophysiological event 
in SCD is abnor mal polymerization of sickle hemoglobin with deoxygenation, which results in 
structural and functional abnormalities of the red blood cell ( RBC). HbS polymerization alters  
RBC membrane  stability, increas es RBC -dependent cellular interactions,  caus es hemoly sis, and 
reduc es sickle  RBC lifespan 53. Besides, the associated membrane abnormalities permit the loss 
of ions and water and result in the formation of dense dehydrated RBCs 54. These abnormal 
RBCs apparently play a central role in disease pathophysi ology, contributing to the two principle 
causal mediators of disease pathology, VOC that mediate s ischemia -reperfusion (IR) injury and 
intravascular hemoglobin release 51,55,56.  
The nature of VOC events in the microcirculation described above are complex . Sickle RBCs  are 
unable to easily traverse small capillaries, enhancing the likelihood of adherent interactions 
between RBCs and the postcapillar y endothelial surface via RBC adhesion molecules such as 
CD36 and integrin a4b1. Frequent sickling and unsickling leads to release of heme loaded RBC 
derived vesicles 57 t hat adhere to the endothelium , promote vascular stasis, alter rheology  and 
trigger vascular occlusion in various organ microcirculatory beds 58. Although the events 
surrounding VOC are  only partially understood, its consequence, ischemia /reperfusion  injury, is 
a profoundly  proinflammatory 55,59-61.  
 
Free hemoglobin released during hemolysis promotes inflammation by scavenging vascular 
nitric oxide, activating toll like receptor 4 (TLR4) on both endothelial cells and leucocytes and 
directly induc ing adhesive (VCAM -1, ICAM, and E- selectin)  and procoagulant (TF) molecul es 
5,6,62-64. Moreover, i ntracellular molecules released during tissue damage  e.g., high mobility 
group box-1 (HMGB1) protein are capable of mediating thrombotic vascular pathobiology in 
15 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 both SCD and VTE 65-68. Intravascular heme stimulate s  neutrophils to release extracellular 
traps in  SCD 69 which can further favor thr om bosis 70. Heme - bound iron stimulates expression 
of placental growth factor in  erythroid  cells 71. This promotes TLR4 signaling in endothelial 
cells and macrophages, activating NF-k B and further triggers vaso-occlusion through Weibel -
Palade body degranulation and adhesion molecule expression in SCD 71,72. Sickled RBCs 
themselves may also directly stimulate thrombosis, based on recent observations of the 
association between sickled RBCs and fibrin in loosely compacted venous clots 73. 
In summary, Hb -S polymerization results in vascular inflammation that can serve as an important 
stimulus for TF -driven activation of coagulation and increased thrombogenic risk. Venous 
thrombosis in SCD is likely mediated by known and unrecognized mechanisms, highlighting the need for additional research to understand key thrombo- inflammatory processes that drive 
vasculopathy. 
Tissue Factor, h ypercoagulability and thrombosis in SCD 
Overview of the hemostatic system and sickle cell disease  
The formation, growth and breakdown of venous thrombi in the vasculature is always in a state of flux between thrombogenic stimuli and protective antithrombotic mechanisms. First identified by Virchow , the triad of thrombogenic stimuli are i) stasis, ii) activation of plasmatic coagulation factors, and i ii) endothelial or vessel wall damage, are all present in patients with 
SCD (Figure 1) 37
,74-76. The protective antithrombotic mechanisms preventing coagulation 
include i) inactivation of activated coagulation factors by circulating inhibitors, ii) clearance of coagulation factors and soluble fibrin polymer complexes by mononuclear phagocytes and hepatocytes, iii) lysis of fibrin by the fibrinolytic system in plasma and endothelial cells. These pathways have almost all been shown to favor t hrombosis in SCD patients, as  reviewed below  
77-79. 
 
Figure 1 Virchows triad in Sickle Cell Disease 
 
The picture can't be displayed.
16 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019  
Increased tissue factor antigen and pro coagulant activity  
TF, the principal trigger of coagulation in vivo , has procoagulant and proinflammatory effects by 
virtue of its ability to signal both intra and extracellularly  80. Although normally separated from 
contact with the plasma coagulation proteins (FVIIa) by an intact endothelial layer, there is a 
growing appreciation of the contribution of “blood borne” TF to thrombosis. In SCD patients, 
blood borne TF is localized to  endothelial cells  5, leucocytes 64  and extracellular vesicles (EVs) 
derived from these cells 81. The number of circulating blood cells and EVs exposing TF 
increases during an acute SCD crisis when compared to the steady state 5,81. In parallel with  
cellular and EV TF antigen expression, whole blood TF procoagulant activity is elevated among SCD patients providing a biologically plausible connection between intravascular hemolysis and coagulation 81-84. TF pathway- m
 ediated  factor Xa generation and subsequently thrombin (IIa) 
formation results in intravascular coagulation and eventual form ation of an  insoluble fibrin. The 
central role of  TF pathway -mediated  thrombin generation and fibrin deposition provides the 
scientific rationale for targeting TF to reduce pathological thrombosis.  
Biochemical markers of F actor Xa and thrombin 
Thrombin pla ys dual pro- and anti- inflammatory roles but is amongst the most potent of 
biological stimulatory molecules for endothelial cells and platelets. Plasma thrombin (evidenced by elevated prothrombin fragment F1.2 [PF1.2], thrombin- antithrombin complexes (TAT), 
fibrinopeptide A, and fragment E levels) is elevated in SCD patients during acute crises and when patients ar e in their steady state 1. Increased thrombin generation is also suggested 
indirectly by elevated factor VII turnover, enhanced platelet activa tion, and reduced anti-
thrombin (AT), proteins S and protein C levels 1. Proinflammatory effects of thrombin result in 
endothelial release of vasoactive substance von Willebrand Factor (vWF), prostacyclins, plasminogen activator and platelet activating factor, along with increased expression of endothelial adhesion molecule and P -selectin expression, that could contribute to or worsen 
vaso-occlusion. The prothrombotic cycle is completed by thrombin mediated platelet activation 
and subsequent platelet release reactions that accelerate and propagate coagulation.  
Evidence for Hemostatic perturbation from murine models of SCD  
L
imitations notwithstand ing, murine models provide insights into the complex vascular 
pathobiology of SCD highlighting in particular the involvement of red cell sickling, 
inflammation, adhesive events, coagulation, vascular stasis, reperfusion injury, deficient nitric oxide (NO) bioavailability and oxidative biochemistry 85- 90. Clearly , 
the proinflammatory SCD 
milieu through distinctive yet intersecting pathways cooperatively recruits  coagulation molecules 
(TF and thrombin), cellular components of blood (leucocytes, endothelial cells, and platelets) 
and extracellular vesicles to promote stasis, thrombosis and vasculopathy 58,91,92. Th at TF is a 
key player in this pathophysiology is apparent from studies in which mice engineered to express 
low TF  levels (1%) and transplanted with HbSS bone marrow stem cells demonstrated a 
reduction in vascular inflammation, endothelial cell injury, and cellular stasis 93,94. Moreover, 
its capacity to incite organ specific thrombotic pathophysiology is demonstrated by higher endothelial luminal surface TF expression in pulmonary veins of Berkeley SS mice unrelated to 
dietary fat intake 95. Subjecting such mice to transient hypoxia followed by reoxygenation 
17 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 upregulates pulmonary vein TF expression above the baseline, a phenomenon reversible by 
lovastatin  95. Since t hr ombo -inflammatory pathology in SCD appears to be mediated  by 
abnormal TF expression and procoagulant activity, lowering TF expression or reducing its procoagulant activity would be an attractive strategy to pursue to prevent VTE in SCD patients.  
Endothelial – Leukocyte – P
 latelet mediated inflammation in SCD 
Recurrent adhesive events and VOC leave the cellular components of blood and vascular endothelium in a state of constant activation. B etween crises, when patients report themselves to 
be in “steady state”, their  baseline biochemical inflammation markers remain abnormal 
supporting the notion of  a persistent  chronic inflammatory state. Activation of vascular 
endothelial cells itself seems necessary but not sufficient to mediate vaso -occlusion. S ickle 
erythrocytes are key  contributors to the occlusion of smaller vessels  whereas  in post capillary 
venules , it is possible that a ctivated , adherent leukocytes are likely drivers of vaso-occlusion 96. 
Additional factors favoring a prothrombotic state include decreased thrombomodulin, TF 
pathway inhibitor, and incr eased release of von Willebrand factor. Lastly, in addition to inducing 
sickling, hypoxia promotes development of a highly prothrombotic proangiogenic microvascula r 
environment favoring fibrin deposition, stasis and ultimately vascular thrombus formation 97,98. 
 
P-selectin found in storage granules of resting endothelial cells and platelets is rapidly 
transferred to the cell membrane  during inflammation  and cellular activation. Endothelial surface 
P-selectin expression mediates abnormal rolling and static adhesion of sickle erythrocytes in 
vitro  99-101  and prompt adhesion of sickle erythrocytes to vascular endothelial cells  followed by 
vascular occlusion in transgenic mice with SCD 90,101-103. Importantly, SCD mice deficient in 
P- and E- selectin demonstrate defects in  vessel wall leukocyte recruitment and are protected 
from vaso -occlusion 101,102,104. I n  transgenic mice expressing  human HbS , adherence of sickle 
erythrocytes and leukocyte to the endothelium is substantially reduced by pharmacological P-
selectin block ade 101,105. P- sel ectin also drives TLR -4/heme dependent complement mediated 
endothelial attack that contributes to vessel wall inflammation in several hemolytic disorders including SCD 106.  
In humans, P- selectin shed ding from vascular cells is increased in  cardiovascular disease, sepsis, 
and cancer  and its levels in some situations are predictive of venous t hromboembolic events 107. 
In a prospective study of 687 cancer pat ients followed for a median of 415 days, the risk of VTE 
was 2.6 (95% CI, 1.4-4.8) times higher among those with levels higher than the 75th percentile 
compared with cancer patients with levels below the upper  quartile  108. The cumulative 
probability of developing VTE 6 months after study inclusion was 11.9% in patients with elevated  soluble P- selectin levels and 3.7% in those with lower levels  108. Soluble P- s
 electin 
levels predict VTE recurrence risk but wh ether they have causal relevance in venous thrombosis 
remains to be elucidated 107,109. Besides, while soluble P- se lectin levels are elevated in SCD 
patients 110, no studies have evaluated their utility in predicting VTE. Selectins mediate 
adhesive cell -cell interactions and in SCD patients favor the formation of hetero -cellular 
aggregates that alter vascular rheology 111,112. A clinical trial of an  a nti P-selectin antibody 
targeting the P -selectin/PSGL -1 interaction reduced sickle cell crisi s rates by 45.3% compared 
with placebo, simultaneously prolonging the time to the first and second crises 4. As a 
18 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 consequence, a phase 3 study of this agent is ongoing ([STUDY_ID_REMOVED]) and several other selectin 
antagonists are in advanced phase clinical trials ( [STUDY_ID_REMOVED]).  
Regulatory control of Tissue Factor  
TF is the principal initiator of coagulation in vivo  80. TF binding to plasma FVIIa, leads to 
formation of a TF–F VIIa complex that triggers the coagulation  cascade by activating both FIX 
and FX. Thus, in the interest of preventing catastrophic intravascular coagulation, the genetic and posttranslational regulation of TF is tightly controlled 113
,114. In the health y  state, TF 
expression is limited primarily to  perivascular and epithelial cel ls, but inflammatory conditions  
induce TF expression in circulating monocytes or vascular  endothelial cells, by activation of TF 
gene trans cription . In sepsis, monocyte TF expression leads to disseminated intravascular 
coagulation whereas surface TF expression by tumor endothelium and subsequent release of TF+ 
vesicles favors venous thromboembolism 115,116. Irres pe ctive of its cellular source and whether 
it is induced or expressed constitutively, most cell surface expressed TF is  in an ‘encrypted’ 
inactive confirmation and demonstrates little or no pro -coagulant activity 114.  
Current literature supports the notion that low levels of TF  are measurable in blood, so called 
“blood- borne TF” 80,117. However, blood- b orne TF is  either fully encrypted or inactivated by 
plasma inhibitors, i.e., tissue factor pathway inhibitor (TFPI). Among several proposed mechanisms to explain TF decryption, externalization of phosphatidyl serine ( PS) to the outer 
leaflet of plasma membrane and oxidation of a TF disulfide bond appear most plausible  118
,119. 
In support of the former are in vitro studies that require TF  association with phospholipids for 
expression of its procoagulant activity , with anionic phospholipids, such as PS, in the 
phospholipid mixture markedly increasing that activity 118,120. Due to their high surf a ce PS TF+ 
EVs do not appear to require decryption to exhibit pro coagulant activity.  
The observations that cell  surface expressed TF  contained free thiols , and that cellular activation 
with ionomycin or HgCl2 depleted free thiols in TF led to the suggestion that Cys186-Cys209 
disulfide bond formation changes the conformation of TF facilitating  the binding of substrates 
FIX and FX  121. Support for t his hypothesis is the observation that m utagenesis of Cys186 and 
Cys209 residues which prevents the formation of a Cys186-Cys209 disulfide bond, severely 
impairs TF pro coagulant activity in several cell types  11,122. Biochemical studies using purified 
placental TF show that reduction of the allosteric disulfide bond in TF does not affect TF binding to FVIIa but results in a  complete loss of TF co -factor function  123. 
Oxidation o f an allosteric disulfide bond of TF to regulate TF pro coagulant activity is likely 
achieved by disulf ide regulatory  switch ing 119,124, a function exhibited by protein disulfide 
isomerase (PDI, see section 2.7) 119,125. PDI associated with the extracellular domain of TF on 
the surface of keratinocytes maintain s TF in a low pro-coagulant s tate, supporting its role as a 
regulator of TF 11. In vivo studies using a murine injury induced thrombosis model revealed that 
inhibition of PDI released by adherent platelets and disrupted vessel  wall cells at the injury site 
decreased TF  triggered  fibrin deposition 12. In another murine vascular thrombosis model, time -
dependent increase s in PDI were observed in vessel thrombi and PDI  inhibition (using either 
bacitracin or a function- blocking mAb) abrogated thrombus/ fibrin formation 10,126. These 
studies suggest that PDI plays a key role in regulating TF mediat ed thrombin generation at the 
site of vascular injury.  
19 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 Vascular Protein Disulfide Isomerase: thrombosis and tissue factor regulation 
Thiol isomerases contain a thioredoxin -like domain and function as reductases, oxidases, or 
isomerases. The archetypical and most abundant thiol isomerase PDI, is a 57 kDa thiol 
oxidoreductase isolated mainly from cellular endoplasmic reticulum (ER) where it possesses 
chaperone and protein folding functions. PDI is also located at the surface of the plasma 
membranes of  platelets, endothelial cells and the vessel wall  where it can act on extracellular 
substrates involved in thrombosis, specifically integrin s 125,127. Va scular wall injury  prompts 
PDI release from disrupted endothelium and bound platelets . PDI at the cell surface pro motes  
thrombosis via disulfide modification of covalently -bound substrates , specifically 
thrombospondin, vitronectin and TF decryption 125,128,129. P DI ’s role  in thrombus formation 
has become evident from several murine vascular thrombosis models 12,126. Th e  hypothesis that 
plasma PDI acts on intravascular coagulation protein substrates to prime thrombus formation 
following vessel injury or activation is therefore consistent with current observations. Global inhibition of vascular thiol isomerases interferes  with this “prim ing” of molecules involved in 
coagulation and blocks thrombus formation in animal models.  
 
F
igure 2. Surface PDI in RBCs membranes. Figure taken from Prado et al. 2013. 
By immunoblotting, cell surface associated PDI on sickle RBCs is present  in higher 
concentrations compared to control RBCs (Figure 2) 7. We independently confirmed t hese data 
in our laboratory ( results not shown). It is therefore possible that plasma PDI activity in SCD is 
cell surface associated, a location where it could promote thrombosis via disulfide modification 
and activation of blood borne tissue factor. The origin of RBC surface PDI in SCD is uncertain, but is very likely transferred from endothelial cells, following inflammation and injury (see section 2.3). Further support for PDI as a therapeutic target in SCD comes from the observation 
that plasma PDI activity is elevated in Townes SS mice 7
,13. Pretreatment of these mice with a 
flavonoid inhibito r of plasma PDI activity reduced TNF alpha mediated vascular -occlusion and 
laser vascular injury mediated thrombosis 13.  
In contrast to the abundance of literature on intracellular thiol isomerases, very  little information 
is available on  plasma vascular thiol isomerases in humans. P lasma PDI activity is measurable in  
healthy individuals  (median=330 pg/mL) with low intra -individual variability over time 130. 
Despite a lack of clarity pertaining to  the repertoire of vascular thiol isomerases that participa te 
in thrombo sis, trials of agents that target these molecules in humans are ongoing . However, 
safety features of the flavonoid agents in human clinical trials to date 9,14 suggest that these are 
valid candidates with which to modulate the thrombo -inflammatory axis in SCD. Evaluating PDI 
The picture can't be displayed.
20 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 inhibition with Isoquercetin as a means to prevent thrombosis in SCD is a novel therapeutic 
approach.  
Isoquercetin inhibits PDI and lowers P- selectin  
Flavonoids quercetins are present in food (fruit and vegetables), and epidemiologic studies of 
diets rich in these substances point to potential cardiovascular benefits , specifically decreased 
mortality secondary to myocardial in farction 131 . Quercetin  a small molecule flavonoid inhibits 
the enzymatic activity of  PDI by occupying its  substrate -binding pocket 132 . Structure -a ctivity 
relationship assays showed that all quercetins tested that possessed a glycoside at the third  
position on the C ring inhibited PDI, including IQ and quercetin -3-rutinoside  133,134. IQ (also 
known as quercetin-3-glucoside), has a similar structure and PDI inhibitory activity to quercetin but demonstrates superior bioavailability in humans 134. In healthy volunteers, within 2 hours of 
administration of 1,000 mg oral IQ, reduced plasma PDI activity by 38% compared  with activity 
observed in pre  IQ ingestion plasma (see figure 3 panel A) 9. P eak  plasma IQ concentration 
correlated  with peak plasma PDI inhibition  when  Isoquercetin concentrations were above 4 μM  
(see figure 3 panel B), achieving a median PDI inhibition of 0.69 U/ml 9. In cancer patients, 2 
months of daily 1000 mg oral IQ exposure resulted in a median change in  PDI inhibitory activity 
of >70 % and a median 58 % reduction in soluble P- selectin  14. 
    
Figure  3: Isoquercetin inhibits PDI activity in plasma. A) Comparison of PDI inhibition and quercetin levels 
following administration of Isoquercetin  to healthy adults. B) Box -and-whisker plot of peak PDI inhibition at peak 
quercetin concentrations above or below 4 μM. Figures taken from Stopa et al 2017.  
 
Preliminary Data:  The primary endpoint of this study is to evaluate the effect of I Q on soluble P-selectin, a plasma 
biomarker that predicts future risk of VTE. Our cross -sectional observations (AS Shet unpublished 
data) and published studies demonstrate elevated soluble P -selectin in SCD patients when 
compared to ethnic  matched healthy controls  135
,136. Mo reover , limited data is available on the 
variability of soluble P -selectin in SCD patients sampled over different time points. We therefore 
determined  the variability of soluble P -selectin  using  stored plasma obtained from SCD  subjects 
enrolled on protocol 17-H-0056. Subjects enrolled in this study were sampled at baseline during 
“steady state” when they self -reported to be in their usual state of health and  were at least 8 weeks 

21 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 remote from experiencing an acute painful crisis . Samples were also collected at the end of study 
when patients were at least 8 weeks remote from experiencing an acute painful crisis or blood 
transfusion. Blood samples obtained by routine phlebotomy were anticoagulated in sodium citrate 
containing tubes and processed within 2 hours of collection to  prepare platelet -free-plasma in a 
two-step centrifugation technique . Supernatant plasma thus obtained was  stored at −80°C  until 
analysis using a commercially available ELISA method to detect soluble P -selectin.  
 
 
  
Baseline EOS01020304050P-Selectin (ng/mL)
Mean:   29.79         28.69
SD:       8.409         8.413BaselineEOS
BaselineEOS01020304050P-Selectin (ng/mL)
< 6 months > 6 months
Mean:   31.36 28.29      27.86 29.19
SD :         7.7 9.1         9.1 7.8Baseline EOS0102030405060P-Selectin (ng/mL)
N=29A) B) C)
 
 
Figure 4. A) P- Selectin measurements at Baseline and End of Study (EOS) stages in patients with SCD, B) P -
selectin measurement comparison between two  different groups of SCD patients: < 6 months between Baseline and 
EOS sampling (n=16) and >6 months between Baseline and EOS sampling (n=13) C) Paired test between the 
amount of P -Selectin at Baseline and EOS sampling. No significant differences were obse rved, Wilcoxon test, P 
value > 0.05, N=29.  
  
22 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 2.3 R ISK/BENEFIT ASSESSMENT  
2.3.1 Known Potential Risks 
Quercetin is commonly consumed by humans as it is naturally present in a wide variety of fruits 
and vegetables, especially apples and onions. According to Querces Pharmaceuticals AG documentation, the background consumption of quercetin from naturally occurring sources is 5.9 mg/p/d (0.1 mg/kg bw/d) and 14.7 mg/p/d (0.25 mg/kg bw/d) at the mean and 90
th percentile, 
respectively, for the total U.S. population, with a maximum intake value of 258 mg/p/d (4.3 mg/kg bw/d).   There is extensive literature on the beneficial effects of Quercetin  in animal models, and multiple 
lines of non- clinical data suggest that it should be well tolerated in human subjects . Moreover, 
published and unpublished information support the safety of quercetin including absorption, distribution, metabolism, and elimination (ADME) studies; acute, subchronic, and chronic toxicity studies; carcinogenicity, genotoxicity, and reproductive/developmental toxicity studies; pharmacokinetic studies; and finally, human clinical and epidemiological studies. From  all of the 
available toxicology studies in multiple species, there is an apparent lack of significant adverse 
systemic toxicity. The overall lack of  in vivo  toxicity of quercetin is consistent with its known 
metabolic fate; specifically, its extensive microbial degradation in the gastrointestinal tract of both animals and humans, followed by methylation, oxidation and conjugative metabolic processes that occur in the liver and kidneys and eventual elimination through the bile, feces, and urine. A two -year toxicity and carcinogenicity study in rats by the National Toxicology Program 
(NTP) was  pivotal in establishing safety  of this agent and  the no observed adverse effect level for 
this study was approximately 2200 mg/kg bw/d (highest dose tested) 137 . 
 Published human clinical studies, including a study with levels up to 1000 mg/d (16 mg/kg bw/d) for 12 weeks, showed that quercetin supplementation was safe and did not majorly influence on several measures of oxidative stress and antioxidant capacity  138. The  w
eight-of- the-evidence 
from toxicological sa fety studies, human clinical studies corroborating epidemiological studies, 
together with recent human pharmacokinetic studies, demonstrate s that quercetin is safe for 
intended use as a supplement . Based on the information provided by Querce s AG, as well as 
other information available to FDA, the agency accepted  the conclusion that quercetin is 
generally recognized as safe ( GRAS ) under the intended conditions of use.  
 I
soquercetin (IQ), a flavonoid quercetin, has also completed clinical trials in healthy individuals 
and cancer patients 9,14. A dverse effects reported in these trials include gastrointestinal effects 
such as nausea, reflux, constipation, diarrhea and rare reports of headache and mild ti ngling of 
the extremities . In the Phase 2 study conducted in cancer patients, two patients had epistaxis and 
mild bruising (both grade 1) that were possibly related to IQ  14. There has been no grade 3 and 
grade 4 toxicity associated wit h IQ treatment in either of these two published human studies.   
 
In
 summary, careful analysis of the available information on IQ does not reveal any potential 
serious toxicity that would preclude its use in SCD subjects. Given the safety and tolerability of 
IQ in published human studies 9,138, and the favorable experience with IQ in a published Phase 
23 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 II study in cancer patients 14 discussed in Backg r ound section, we anticipate that testing an 
identical dose of IQ to that currently investigated in other active clinical studies would not pose 
any undue risk in SCD patients.  T
he only tests and procedures done under this study are blood draws, periphera l arterial 
tonometry  and urine collection.  The individual study procedure risks are listed below. 
 
Peripheral Arterial Tonometry (PAT)  (ENDO -PAT 2000, Itamar Medical):  
The use of peripheral arterial tonometry is not associated with any known adverse effects. After the 
procedure, the patient may experience bruising due to microcapillary bursts in their arm – these marks 
should disappear within a week.  
Phlebotomy:  S tandard precautions for obtaining human blood samples will be taken. Transient 
discomfort and minor bruising may occur at the phlebotomy site.  Vasovagal symptoms can 
occur during blood drawing.  Blood samples will be obtained by venipuncture. The quantities of 
blood to be drawn for research purposes will be less than 550 ml, which is consistent with the CC policy as provided in Medical Administrative Series (MAS) 
95-9 (revised 5/29/12): for adults, no more than 10.5 mL/k g/ or 550 mL (whichever is smaller) 
will be drawn for research purposes over any 8 week period.   Once blood samples will be drawn, the samples designated for platelet free plasma (PFP) 
preparation (Biochemicals studies, coagulation studies, contact pathway), and platelet aggregation assays should be processed within 2 hours after phlebotomy. The samples 
designated for red blood c ell studies and leukocytes isolationcan be processed greater than  2 
hours after phlebotomy. .  Urine Collection: There are no known risks to those collections. 
Near infrared spectroscopy (NIRS):  In general, commercial NIR tissue oximetry devices that use similar 
light energy levels have been cleared by the FDA and are classified as “minimal risk.” The current research 
DOS instrument is a type of NIR oximetry instrument that employs comparable levels of NIR light to conventional FDA -cleared  clinical instruments. Although DOS has advanced capabilities for quantitative 
tissue measurements that make it a research tool, the safety/effectiveness of the device is NOT being 
evaluated in this study nor will the data generated be used to support an F DA application for research or a 
marketing permit. 
 There are no risks associated with the use of near infrared light as it has been described in this protocol. The amount of optical energy is too low to cause appreciable tissue heating. Temporary pain or paresthesias may occur during the approximately 3-5 minute blood pressure cuff inflation. The vascular occlusion 
challenge may also result in redness or minor bruising of the limb due to cuff inflation. This occlusion is a 
standard test that is performed in many hemodynamic assessments, such as in the case of peripheral vascular disease. At the NIH Clinical Center, previous studies (including 07 -H-0196 and 12-H-0101) have used 5-
minute brachial artery occlusions in combination with non-invasive imaging moda lities without reporting 
significant safety issues. Subjects will be monitored closely for any concerning signs and symptoms during 
the occlusion challenge, and if there are any concerns for safety or if subjects experience significant 
discomfort, the occlusions will be released immediately.
 
24 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 2.3.2 Known Potential Benefits  
In this supplement study, the prospect of direct benefit is modest. Clinical benefit relates to a 
lowered risk for thrombogenesis if soluble P -selectin and tissue factor activity are reduc ed as 
hypothesized. These benefits are more likely to be seen in those patients with VTE or are at greatest risk for developing VTE.  
 
2.3.3 Assessment of Potential Risks and Benefits  
The risks of the study supplement and the minor procedures included in this protocol are minimal and justified by the potential benefit of expanding our understanding of how flavonoid anti-oxidants may play a role in the thrombotic vascular pathobiology of SCD and at the same 
time employing strategies to minimize the bleeding risk posed by traditional anticoagulation treatments . This supplement has been employed at the same dose proposed in this study without 
any reported adverse effects.  
 
  
25 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 3 OBJECTIVES AND ENDPOINTS  
 Table:1  
OBJECTIVES  ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  
Primary   
 
Evaluate the effect of IQ  on 
thrombo -inflammatory markers  
 The primary outcome will be the change 
in the plasma soluble P -selectin level 
comparing the baseline to IQ  response.  IQ blunts soluble P -selectin and SCD 
subjects exhibit  elevated soluble P -
selectin levels, which is a consistent 
inflammatory signature of this disease.  
Exploratory    
 
Explore whether other thrombo-
inflammatory biomarkers  linked 
to steady state SCD  are affected 
by administration of IQ . 1) Compar e baseline and end of study 
plasma protein disulfide isomerase activity  
2) Quantify  baseline and end of study 
plasma tissue factor positive 
extracellular vesicle number   
3) Compare baseline and end of study 
tissue factor procoagulant activity  
4) Compare baseline and end of study 
platelet thrombin generation  
5) Compare baseline and end of study 
inflammatory cytokines  
6) Compare baseline and end of study plasma D -Dimer, TAT and PF1.2  
7) Compare contemporary biomarkers 
of vascular function and 
atherothrombosis obtained at 
baseline and end of study  
8) Assess safety and tolerability of IQ  
9) Assess adherence to oral IQ  The primary driver of 
hypercoagulability appears to be 
endothelial and monocyte  derived  
tissue factor in SCD, however, other 
cells (platelets and sRBCs)  are linked 
to thrombo -inflammatory signals  by 
the innate immune system and complement  that can trigger 
proinflammatory pathwa ys. 
We will explore the effect of IQ  on 
modulating the intersecting pathways 
of inflammation and  coagulation as 
exploratory end points . 
Simultaneously, we will evaluate safety of intervention and adherence.
 
 
26 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 4 STUDY DESIGN 
4.1 O VERALL DESIGN  
This study is a prospective, randomized, double-blind, parallel group, placebo -controlled study 
where the thrombo -inflammatory  profile of steady sta te SCD subjects will be studied at baseline 
and following 4 weeks of treatment with IQ  or placebo. The allocation of IQ : placebo will be 1:1.  
The screening visit will be used to determine initial eligibility to the protocol.  Final subject 
eligibility will be confirmed on day 0 just prior to receipt of I Q or placebo.  day 0 will be adjusted 
if any changes to patient eligibility occur after screening.  If there is a change in eligibility and  the 
subject will not meet the requirements within 90 days of the screening visit, the subject will be removed from study and may rescreen if/when eligibility  criteria is met.  
All subjects who have completed screening and have met all inclusion criteria and do not have any 
exclusion criteria on D ay 0 of the start of the study drug will receive 28 days + 7days of I Q or 
placebo .  Research parameters at the end of the study will be compared to baseline to determine 
the effects of this intervention.  Research bl ood samples and atherothrombotic risk measures to 
monitor primary and exploratory  study end points will be obtained during baseline after enrollment 
(Day 0, visit #2) and after 4 weeks exposure to I Q/placebo (D28, visit #3). 
. 
SCD patients will be defined as being in the “steady state” if they report clinical symptoms to be 
their baseline and are at least 60 days remote from an acute “crisis”. Adapting from the Multicenter Study of Hydroxyurea trial 139, a crisis will consist of “a visit to a medical facility for acute pain 
that has no evident cause other than SCD, for which the patient requires hospital attention, either as in - or out -patient, and i s treated with parenteral narcotics”. Patients receiving hydroxyurea as 
disease modifying therapy must have been on the same dose for at least 90 days to be defined as “stable”.  
To adhere to the intention- to-tre
 at principle, for every  patient that is  randomized , we will attempt 
to obtain 28 -day endpoint measurements despite occurrence of expected and /or unexpect ed events 
due to the underlying disease  that may influence biomarker end points . Therefore,  in the event of 
their  occurrence, clinical SCD related complications will be handled as described below :  
 Study participants experienc ing “acute pain crisis” < 7 days of initiating 
drug or placebo will be instructed to discontinue their study drug. These 
participants will not resume study drug but the research team will attempt 
to obtain their 28- day endpoint measurement.  
 Study participants experiencing stroke or acute chest syndrome requiring exchange transfusion during the 28 -day study drug treatment window will 
discontinue study drug. T hese participants will not resume study drug but 
the research team will attempt to obtain their 28 -day endpoint 
measurement.  
 Study participants experiencing an “acute pain crisis” between 7 - 28 days 
of treatment with either drug or placebo will continue treatment and 
complete end of study activities  according to the protocol. 
27 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019  
 
 Study participants experiencing VTE or an acute febrile illness (fever 
101°F, requiring admission to the hospital and IV antibiotic treatment ) 
and/or require simple transfusion during the 28- day study drug will 
continue study drug treatment and complete end of study activities 
according to the protocol. 
 
 At any time, the investigator may suspend the study medication for 
reasons related to safety or tolerability.  
 
 For patients who are unable to provide a 28 -day end of study measurement 
see section 9.4.6. 
 
 
 
 
4.2 S CIENTIFIC RATIONALE FOR STUDY DESIGN  
This is a pilot  phase II study and the number of subjects w as chosen to provide good statistical 
power to detect a 25-30% reduction in plasma soluble P- selectin, a clinically meaningful 
thrombo-prophylactic benefit, similar to that observed in cancer patients (see power analysis in 
section 9). Such an effect would simultaneous ly offer the potential to  explore the effects of PDI 
inhibition on post- translational regulatory control of TF. A parallel group double blind placebo -
controlled  study would be the most effective study design in which to enroll and complete the 
subject group in the proposed protocol with minimal risk for study withdrawal due to frequent 
acute painful crises.  
 
4.3 J USTIFICATION FOR DOSE 
Investigators at Harvard University , Massachusetts previously reported that oral administration 
of 1000 mg IQ once daily  to healthy adults, was well tolerated, readily absorbed, and detectable 
in human plasma [the measured peak plasma quercetin concentration (9.2 μM) exceeded its IC50 
for inhibition of PDI by IQ  in vitro  (2.5 ± 0.4 μM) ]9. The same group of investigators recently 
published a  phase II clinical trial  of IQ at two doses (500 mg and 1000 mg  once daily ) to 
evaluate its effects on preventing thrombosis in cancer patients14. In this s tudy, IQ (1000 
mg/day) achieved optimal plasma PDI inhibition  (73.3% median change in PDI inhibitory 
activity) and lowered soluble P- selectin levels (-58% % median change, P <0.001), with no 
detectable toxicity . However, t he 500 -mg dose failed to  achieve a significant reduction in soluble 
P-selectin in cancer pat ients ( -0.3%, P=0.26) 14. Taken together, these data suggest that 1000 mg 
of IQ once daily is an optimal starting point to evaluate restoration of perturbed thrombo-
inflammatory processes in SCD patients.  
 
28 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 5 STUDY POPULATION 
5.1 I NCLUSION CRITERIA  
For enrollment onto the active phase of the study (IQ supplement vs placebo), subjects must 
meet all of the following criteria during the screening period (visit #1) which can last from 0 -28 
days prior to start of study intervention: 
5.1.1 Unequivocal diagnosis of sickle cell anemia (HbSS or HbSß0thal or  HbS ß+thal or 
HbSC) confirmed by hemoglobin electrophoresis performe d on patients at least 
90 days after a blood transfusion if previously transfused, or DNA genotyping. 
5.1.2 Age  18-70 years old  
5.1.3 Steady state SCD (no acute vaso -occlusive crisis within 60 days of D0 of the 
study) and if on HU therapy, on an optimized dose  for a t least 30 days. For those 
newly initiated on HU therapy, the dose should be unchanged for at least 90 days  
5.1.4 Be willing to comply with all study procedures for the duration of the study.  
5.1.5 Have provided signed written informed consent prior to performing any study procedure, including screening procedures. 
 
5.2 E
XCLUSION CRITERIA  
Subjects who meet any of the following criteria during screening will not receive the 
study intervention and will be counted toward study accrual. Screen failures will not be 
included in the analysis  for statistical purposes:  
 
5.2.1 SCD with a recent VOC (<60 days from D0 of study).  
5.2.2 SCD with history of recent blood transfusion (<60 days from D0 of study) or exchange transfusion (<90 days from D0 of study).   
5.2.3 SCD with a recent VTE (within 90 days of diagnosis of either DVT, PE or both).  
 
5.2.4 Any patient receiving crizanlizumab therapy for SCD or that has received crizanlizumab within the past 30 days of D0 of study.      
5.2.5 Have a significant medical condition that confers an unacceptable risk to participating in the study, and/or that could confound the interpretation of the study data. Such significant medical conditions include, but are not limited to the 
following:  
a. History of recent (within 3 months prior to signing informed consent) 
congestive heart failure; myocardial infarction or unstable angina pectoris; hemorrhagic, embolic, or thrombotic stroke. 
29 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 b. Active infection requiring the use of parenteral antimicrobial agents or 
Grade ≥3 in severity (per National Cancer Institute Common Terminology Criteria for Adverse Events  v5.0) within 2 months prior to 
the first dose of study drug . 
c. Active viral infection as evidenced by testing positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody (Ab) with signs of active hepatitis B or C virus infection. If the subject is positive for HCV  
Ab, a reverse transcriptase- polymerase chain r eaction test will be 
conducted. Subjects with hepatitis C may be rescreened after receiving appropriate hepatitis C treatment.  
d. Testing positive for human immunodeficiency virus (HIV)  1 or 2 Ab 
with evidence for ongoing active infection (i.e., CD4 count <400/µL and viral load >100,000 copies/mL ) on antiretroviral therapy . 
e. Active acute inflammatory disorders rheumatoid arthritis or systemic lupus erythematosus on disease modifying therapy. 
f. Diabetes mellitus judged to be under poor control by the Investigator evidenced by a single fasting sugar value >250 gm/dl or requiring >3 antidiabetic agents, including insulin (all insulins are considered 1 agent); use of insulin per se is not exclusionary. 
g. History of any primary malignancy, with the exception of curatively treated nonmelanomatous skin cancer; curatively treated cervical or 
breast carcinoma in situ; or other primary tumor treated with curative 
intent, no known active disease present, and no treatment administered during the last 3 years. 
h. Any injury or medical condition  that, in the  judgement of the 
Investigator.would prevent the subject from participating in the study  
 
5.2.6 Have a prior bone marrow or stem cell transplant. 
 
5.3 I NCLUSION OF VULNERABLE PARTICIPANTS  
Vulnerable subjects will not be included in this study. 
5.4 L IFESTYLE CONSIDERATIONS  
During this study, participants are asked to: 
• Refrain from making major  changes in dietary intake or physical activity during the 6 
weeks of active study participation.  
30 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 5.5 S CREEN FAILURES  
Screen  failures are defined as participants who consent to participate in the clinical trial but are 
not subsequently assigned to the study intervention.  The se subjects will sign consent and will 
receive a study ID . 
Individuals who do not meet criteria for participation based on an abnormal clinical history or 
laboratory test result may be rescreened  if warranted , with  assign ment of a new  participant ID  
number from  the initial screening.  
 
5.6 S TRATEGIES FOR RECRUITMENT AND RETENTION  
Subjects with steady state sickle cell disease will be recruited from the  sickle cell clinic at the 
NIH CC. We will also recruit subjects through NIH using traditional recruitment methods such 
as referrals from other protocols, outside physician referral and self -referral.  
The study may opt to use the following strategies for recruitment of patients:  
• ClinicalTrials.gov website 
• Clinical Center Research Studies (“Search the Studies”) website  
• Sickle Cell Anemia Research Fund website  
• National Heart, Lung and Blood Institute (NHLBI) patient recruitment website  
• Twitter messages and chats with study investigators  
• Facebook Posts 
• Google AdWords 
• Use of Clinical Center Office of Patient Recruitment services including creation and distribution of study flyers and information through pre -existing recruitment avenues 
such as the NIH recruitment listserv.  
The DIR Patient Recruitment Office (PRO) will work with study investigators to ensure accrual goals are being met.  All recruitment materials and tools will use IRB -approved language and 
infor mation to include standard recruitment contacts.  
We expect to screen up to 60 subjects to enroll 46 eligible study participants. 
5.6.1 Costs  
There will be no anticipated costs that the subject will be responsible for.  
5.6.2 Compensation 
Subjects will be compensated for some of the procedures that are performed at the NIH since they may not provide direct benefit to the subject.   They will be compensated by check or direct deposit 
at the end of the study or  at the time of study withdrawal for the procedures completed.  Payment 
will typically be received within 2 months of the last study visit.  
Table : 2  
31 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 Procedures  Inconvenience 
Units  Compensati on 
per procedure  Frequency  Total 
Compensation  
Outpatient visit ($20 first hour, $10 
each additional hour)  4 hrs  $50 3 $150 
Medical History and physical 
 2.5  $35 3 $105 
Research Blood Draw  6 $60 2 $120  
Labs  5 $50 2 $100  
ENDO -PAT  (optional)  1 $50 2 $100 
NIRS  (optional)  1 $50 2 $100  
24-hour Dietary Recall  1 $15 3 $45 
Phone call  1 $10 1 $10 
Compliance incentive ($200) All 
    
 $200  
  Total Compensation:  $ 930 
 
 
Reimbursement for local travel will be provided. We will reimburse for car mileage up to 30 miles 
each way. We will also reimburse for train and bus.   
Reimbursement for food and lodging will  not be provided. 
 
6 STUDY INTERVENTION 
6.1 STUDY INTERVENTIONS (S) ADMINISTRATION  
6.1.1 Study Intervention Description 
The study will use the dietary supplement IQ  or a placebo capsule. IQ is a derivative of the 
commercially available form of  flavonoid Quercetin s, small -molecule inhibitors of PDI that block 
thrombus formation . Considering that the clinical investigation is designed to study the 
relationship between a dietary supplement’s effect on structure or function in humans or to 
characterize the mechanism by which a dietary supplement acts to maintain such structure or function, this study would not need to be conducted under an IND. However, the IQ formulation 
proposed for use  is not marketed in the United States and is manufactured overseas by Querces 
AG.  Moreover , the dose proposed for the clinical investigation (1000 mg) is higher than the dose 
for which it is marketed as a dietary supplement  (250 mg). Thus, this study will be conducted 
under an IND.   
32 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 6.1.2 Dosing and Administration 
Subjects will take four capsules by mouth (250 mg IQ or identically formulated placebo) once 
daily for a total of 4 weeks (+ up to 7 days if needed).  
 6.1.3 Dose Escalation  
N/A 
6.1.4 Dose Limiting Toxicity  
N/A 6.1.5 Dose Modifications 
IQ is not expected to result in any protocol- related SAEs.   Therefore, no dose modifications are 
planned. 
6.1.6 Drug Administration 
Subjects will  take four capsules by mouth (250 mg IQ  or identically formulated placebo) once 
daily for a total of 28 days (+7 days if needed) .  Capsules must be taken whole and may be taken 
with or without food. The capsules should be taken at a fixed time in the morning (e.g. 9.00AM 
according to subject convenience).  If a dose is missed and it is more than 6 hours before the next dose is due, then the dose can be taken.  If a dose is missed and it is less than 6 hours before the dose is due, then the dose should be skipped.   
 6.2 P
REPARATION /HANDLING /STORAGE /ACCOUNTABILITY  
6.2.1 Acquisition and Accountability  
Both IQ  and placebo will be obtained from Querces AG .  Product will be stored and dispensed 
by the NIH CC Pharmacy.  Unused product will be returned to the clinical center and destroyed . 
6.2.2 Formulation, Appearance, Packaging, and Labeling   
Common name:   Isoquercetin  
Product name:   Isoquercetin  
Chemical name:  Quercetin -3-glucoside  
Daily dose:   1000 mg x 4 wk 
Route of administration:  oral 
Dosing instructions:   1000 mg (4 capsules of 250 mg ) once daily  
Supply:   Supplements will be obtained from Querces AG . 
Toxicology:   None known 
Drug Interactions:   None known 
The capsules will be put into individual bottles, labeled and dispensed by the NIH Clinical Center pharmacy.  The label will include at a minimum the study ID and instructions for taking the supplement or placebo.  
Each 250- mg c apsule contain s ascorb ic acid (62 mg) and niacin (5 mg) to prevent oxidation 
during storage and has previously been shown to not influence IQ  pharmacokinetics.  
33 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 The placebo will be manufactured and supplied by Querces AG  to match the active supplement  
and additives.  
 
6.2.3 Product Storage and Stability 
IQ and placebo will be stored in the pharmacy at room temperature in light restricted containers . 
 
6.2.4 Preparation 
N/A 6.3 M
EASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING  
Patients will be randomized in a block randomization scheme with block sizes of 2 and 4 
randomly generated by an unblinded study statistician  who is not the primary statistician for the 
study. In this double-blind study, t he clinical study team and primary statistician will be blinded 
to the randomization assignments  until enrollment is complete and the assays performed for 
assessment of the primary endpoint. Isoquercetin and placebo will be supplied in identical 
formulations to allow blinded administration.  
The investigator will not be provide d with randomization codes. The codes will be maintained 
with the NIH Pharmacy, which has the functionality to allow the investigator the break the blinded allocation for an individual subject.  
Under normal circumstances, the blind should not be broken unt il completion of the study or if 
the Independent Data Safety Committee Board  (DSMB) makes a recommendation for unblinding 
that is accepted by the PI.  
6.4 S
TUDY INTERVENTION ADHERENCE  
Study capsule adherence will be monitored using patient report in the form of a capsule  diary and 
capsule coun ts performed  by the research team  during Visit 3.   
6.5 C ONCOMITANT THERAPY  
Excepting folic acid, s ubjects should not take any other multivitamins or supplements for the 
duration of the study. 
It is recommended patients take f olic acid, at least 1mg PO daily while taking the study 
supplement, IQ. For patients in which f olic a cid is not part of their SCD management, a 30 -day 
supply of 1 mg of folic acid will be prescribed , to be taken once daily . Upon study enrolment and 
randomization, subjects will initiate  folic acid with  IQ and discontinue it at the end of the study. 
Subject will be asked if they were adherent to folic a cid but a formal pill count will not be 
performed .  
34 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL   
7.1 D ISCONTINUATION OF STUDY INTERVENTION  
The supplement has a good safety record and we do not expect any significant adverse events. A 
DSMB will evaluate safety trial data based on the below  triggers  and if warranted, may 
recommend modification or even termination of this protocol. Stopping rules follow a Bayesian design. The stopping rule is designed to halt enrollment for further evaluation of study data by the safety committee and determination whether enrollment can continue, or the study should be modified or terminated.  A Bayesian posterior probability will be calculated to determine the 
likelihood the probability of having a qualifying adverse event is 25% or more.  
Qualifying AEs/SAEs  for the stopping rule will be counted only in the Isoquercetin arm (and not 
in the placebo arm), will be monitored for reaching the stopping boundary by the unblinded 
statistician, and  are any of the following three types of events: 
• Any Grade ≥3 treatment related SAE  (these include acute painful crises that are probably 
related to the intervention),  
• Grade 4 bleeding, related to Isoquercetin  , 
• Any non- hematological AE Grade ≥ 3 related to IQ  
 
7.2 P ARTICIPANT DISCONTINUATION /WITHDRAWAL FROM THE STUDY  
Participants are free to withdraw from participation in the study at any time upon request.  
An investigator may discontinue or withdraw a participa nt from the study for the following 
reasons:  
1) Subject taking less than 75% of their capsules 
2) Subject found to be pregnant or wishes to breastfeed during the study will automatically 
be withdrawn 
3) Subject found to be taking or electing  to take multivitamins or supplements while on 
study supplement, Isoquercetin. This does not include f olic acid.  
4) If subject no longer wish es to participate  
5) Per PI discretion , for development of a SCD related complication  that does not  permit 
study participation.  
  
Prior to removal from study, any subject who has started the study intervention should complete 
a safety assessment phone call .  If a subject requests withdrawal early for any reason, we will 
make every effort to have them complete an  unscheduled safety assessment phone call  and a 
35 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 clinic visit if indicated . Subjects experiencing side effects during the 28-day Isoquercetin/placebo 
treatment may have a clinic visit during the study.   
The reason for participant discontinuation or withdrawal from the study will be recorded in the 
source document. Subjects who sign the informed consent form and are randomized but do not receive the study intervention may be replaced.  Subjects who sign the informed consent form, and are randomized and receive the study intervention, and subsequently withdraw, or a re 
withdrawn or discontinued from the study, will be counted toward the accrual ceiling of 46. Randomization will continue until either the accrual ceiling of 46 is reached . 
 
7.3 L
OST TO FOLLOW -UP 
A participant will be considered lost to follow -up if he or she fails to return for the scheduled 
visits and is unable to be contacted by the study site staff.  The following actions must be taken if a participant fails to return to the clinic for a required 
study visit: 
• The site will attempt to contact the partic ipant and reschedule the missed visit  to another 
day within 7 days of the scheduled visit,  and counsel the participant on the importance of maintaining the assigned visit schedule and ascertain if the participant wishes to and/or should continue in the study.  If the visit cannot be rescheduled within the 7 day 
timeframe, then the patient will be considered lost to follow -up.  
• Before a participant is deemed lost to follow -up, the investigator or designee will make 
every effort to regain contact with the pa rticipant (where possible, 3 attempts at contact) 
These contact attempts should be documented in the participant’s medical record or study file.  
• Should the participant continue to be unreachable, he or she will be considered to have withdrawn from the study with a primary reason of lost to follow -up. 
 
8 STUDY ASSESSMENTS AND PROCEDURES  
8.1 S
CREENING PROCEDURES  
 Screening activities performed prior to obtaining informed consent Minimal risk activities that may be performed before the subject has signed a consent include the following:  
• Email, written, in person or telephone communications with prospective subjects • Review of existing medical records to include H&P, laboratory studies, etc.  
 Once the research team has identified a potential subject for the study, the subject will be asked to come to the NIH.  The study team will consent the subject, allowing time for the subjects to ask questions and make a voluntary decision.  
36 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 Once the subject signs the consent,  the following tests  will be done at the Screening Visit unless 
any of the tests have been performed under another NIH protocol 90 day prior to signing the 
consent (unless otherwise stated).  
 
Screening Visit:  
o History and physical exam including prior transfusion history  
o CBC with differential  
o  Reticulocyte count 
o Acute care panel, Mineral panel, Hepatic panel, total protein, creatinine kinase, uric acid, lactate dehydrogenase  
o Calculated creatinine clearance  
o Serum HBsAg, anti- HBc, anti -HBs, anti -HCV, anti -HIV 
o Coagulation screen (PT/INR, PTT, fibrinogen, D- dimer)  
o Pregnancy test (serum or urine) for female subjects and use of barrier methods of contraception for male subjects  
o Hemoglobin electrophoresis 
 
Up to 60 subject will sign consent to be screened with the goal of enrolling 46 subjects eligible to participate in the interventional portion of the study.  
 
8.2 S
TUDY EVALUATION PROCECURES  
Study Procedures will be conducted per table in section 1.3 (SOA) and are described below .  The 
effectiveness of IQ in reducing P- selectin levels will be assessed as described in section 9. 
Physical examinaton and medication history :  
A physical examination, review of  medica tion history, and review of available laboratory tests 
may be completed o n each subject. Medical records obtained under other protocols may also be 
reviewed. Vital signs and biophysical data (blood pressure, heart rate, respiratory rate, temperature, height, and weight) may also be collected at each visit. These measurements wi ll be 
made per NIH Clinical Center policies.   
Optional exploratory studies of peripheral arterial tonometry and/or NIRS will based on service availability and  may be conducted in patients that agree to this procedure.   
Peripheral Arterial Tonometry (PAT)  (ENDO -PAT 2000, Itamar Medical):  
PAT is an FDA -approved noninvasive technology that captures a beat- to-beat plethysmographic 
recording of the finger arterial pulse wave activity with pneumatic probes, which provides a 
measure of endothelial function, sim ilar to that of brachial artery ultrasound (BAUS) assessment 
of flow mediated dilation.  It is claimed that this method is highly automated, consistent, and operator independent.  
The PAT finger probe consists of a thimble -shaped sensor cap that imparts a uniform pressure 
fields and exhibits a clamp -like effect on the entire surface of the distal phalanx and measures 
pulsatile volume changes.  PAT applies a significant counter pressure (70 mmHg) on the digit to avoid distal venous distention, thereby inhibiting venous pooling and blood stasis, which could otherwise induce a veno -arteriolar reflex vasoconstrictor response.  
37 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 Near  Infrared Spectroscopy (NIRS) :a. Additional non- invasive studies relating to muscle 
physiology, tissue oxygenation and blood flowmay also be assessed using near infrared 
spectroscopy (NIRS) methodologies. The red to nearinfrared (NIR) part of the electromagnetic spectrum (600 to 1000 nm) allows photons to penetrate a few centimeters below the surface of the skin. These photons are non- ionizing and do not induce local heat. There are numerous FDA 
cleared clinical instruments in wide use that employ NIR light for non -invasive muscle and brain 
tissue oximetry. Quantitative optical spectroscopy in the NIR allows for safe, non-invasive measurements of the concentrations of blood, water, and lipids in tissues.Caliper measurements are used to measure the thickness of the skin to approximate tissue depth. We will use a number of different NIRS technologies to precisely and accurately char acterize tissue metabolism, 
composition, and perfusion in subjects with SCD. These technologies, used in combination with non-invasive perturbations to evaluate vascular health (vascular occlusion challenge and 
respiratory challenge), are described below:  
 b. Diffuse Optical Spectroscopic Imaging (DOSI): DOSI is a progression on continuous -wave 
NIRS techniques that utilizes a frequency -modulated light source that allows for quantitative 
measurement of blood, water, and lipid concentrations in tissues. DOSI requires more advanced hardware than traditional NIRS techniques but is similarly safe and non -invasive. 
 c. pocketNIRS: This is a portable NIRS device developed by Hamamatsu Photonics in 
conjunction with the Tromberg lab. pocketNIRS consists of a control unit and 2 probes with 3 light emitting diodes (740nm, 800nm, 850nm) and can be controlled via cell phone. It measures changes in oxyhemoglobin, deoxyhemoglobin and total hemoglobin and also gives absolute measurement of tissue saturation.  d. Laser Speckl e Imaging (LSI): (LSI is a NIRS technology that is sensitive to flow. LSI consists 
of a coherent non- collimated light source (typically 785 nm) and a camera that images the 
illuminated tissue area. When biological tissue is illuminated with coherent light,  an interference 
pattern will be formed at the detector, known as a speckle pattern. Blood flow speed affects the pattern captured by the camera and characterizing these changes in the pattern allows for a measurement of blood flow in the skin microvascula ture. 
 e. Affixed Transmission Speckle Analysis (ATSA) (trade name: FlowMet -R): FlowMet is the 
contact, transmission based equivalent of LSI. Within this device, the source and detector are on opposite sides of the finger. Light that shines through the finger or toe is picked up by the camera on the other side. Blood flow speed affects the pattern captured by the camera. Characterizing these changes in the pattern allows for a measurement of arterial blood flow within the finger or toe.  
f. Diffuse correlat ion spectroscopy (DCS): DCS uses a 785 nm coherent light source with a 
detector some distance away. DCS measures the temporal fluctuations of near -infrared (NIR) light 
to measure flow in the microvasculature at a single point.  
 
g. PeriFlux 6000 for microcirculatory blood flow assessments: The PeriFlux System 6000 device 
will be used for measuring microcirculatory blood flow and oxygenation in the limb and poses a 
38 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 non-significant risk. Diffuse reflectance spectroscopy (DRS) and laser Doppler flowmetry (LDF) 
have been successfully integrated enabling accurate measurements of blood flow and oxygenation 
in the microcirculation. A dedicated fiber -optic probe that integrates the DRS and LDF modalities 
is required as well as an external light source.  
 h. Vascular O cclusion Challenge: Subjects will not have any active role in this challenge. A 
standard blood pressure cuff will be placed upon the limb (arm or leg) to be studied. Subjects may be asked to lie on a gurney or reclining chair for comfort and to keep the occluded limb stable. A DOS probe will be placed on the limb, and continuous measurements using the NIRS methodologies described above will be taken throughout the challenge. Additional optical probes may be placed on other tissue sites, such as the forehead  or non -occluded limb. The FlowMet may 
be used on one of the fingertip/toe in order to monitor blood flow. If the subject does not tolerate limb cuff inflation, we may instead switch to performing a vascular occlusion challeng on the finger using a finger- sized cuff instead.  
 i. Respiratory Challenge: Subjects will be asked to a) pace their breathing according to a specific 
metronome- controlled rate or b) hold their breath for as long as they are able. Participants may be 
asked to lie on a gurney or reclini ng chair for comfort and to aid in reducing motion artifacts in 
data. An optical probe will be placed on at least one tissue site and will collect data continuously during paced breathing. To better understand how muscle oxygenation and blood volume change s 
during this challenge, additional optical probes may be placed over the top of other tissue sites (e.g. shin bone, abdominal adipose tissue, forehead, etc.). Data from these additional locations does not increase the risk to participants and only adds more physiological context to data from muscle locations.  
 
8.2.2 Biospecimen Evaluations 
Biological specimen collection and laboratory evaluations . In addition to the clinical blood 
samples, subject will have research bloods drawn within the blood withdrawal volume limits established by the Clinical Center.  RBC structure and functional studies , Flow cytometry, 
Platelet studies , RNAseq, Immunoblotting, and cytokine profiling may be performed.   
Table :3  
39 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 Table of samples to collect at baseline and end of study  (2 visits)  
Test/assay  Volume 
blood 
(approx.)  Type of 
tube  Collection point 
(+/- 72hrs)  Location of 
specimen analysis  
Routine*  
• Hepatic, Mineral 
and Acute care 
panel  
• LDH , T. protein, 
CK, uric acid  
• C-reactive protein  
• B-type natriuretic 
peptide  
• Beta HCG (Female 
only)   
 
 
 
4 mL   
 
 
LtGrnPSTGel 
(GLT) tube  
   
 
 
Baseline (D0) and 
end of study D28)    
 
 
Clinical Lab  
Routine*  
• CBC 
• Reticulocyte count  
• HPLC for Hb 
electrophoresis  
• Direct antiglobulin 
test (DAT)   
 
9ml 
(3 tubes)   
EDTA tube    
Baseline (D0) and 
end of study D28)    
Clinical Lab  
Routine*  
• PT 
• PTT 
• INR 
• Fibrinogen  
• D-dimer    
3ml   
3.8% Sodium 
Citrate    
Baseline (D0) and 
end of study D28)    
Clinical Lab  
Biochemical studies ** 
• Soluble P-selectin  
• Plasma PDI activity 
assay  
Protein Carbonylation 
state (Western Blot)   
 
3 ml   
3.8% Sodium 
Citrate   
 
Baseline (D0) and 
end of study D28)    
NHLBI Sickle Cell 
Branch, Sickle 
Thrombosis Lab  
 
 
Coagulation studies ** 
• Microparticles/EVs  
• Prothrombin fragment 
F1.2, Thrombin anti -
thrombin complexes 
(TAT)   
 
3 ml 
(1 tube)   
3.8% Sodium 
Citrate    
Baseline (D0) and 
end of study D28)    
NHLBI Sickle Cell 
Branch, Sickle 
Thrombosis Lab  
40 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019  
*Tests necessary for routine care of patient with sickle cell  disease.  
**Research blood samples to be collected at baseline during study enrollment and during follow 
up.   
8.2.3 Correlative Studies for Research/Pharmacokinetic Studies  
N/A 
8.2.4 Samples for Genetic /Genomic  Analysis 
The mononuclear cell fraction will be isolated and stored for gene expression and RNAseq 
specifically looking at tissue factor expression in monocytes and gene variants involving 
thrombo- inflammatory pathways (P- selectin and the complement ). 
  
Red Blood Cell studies ** 
• Deformability  
• Oxygenscan  
• Aggregation 
• ROS production  
• PS and PDI exposure 
and distribution 
(FACS)   
 
6 ml 
(2 tubes)   
EDTA  tube   
Baseline (D0) and 
end of study D28)    
NHLBI Sickle Cell 
Branch, Sickle 
Thrombosis Lab  
Platelet function tests ** 
• Studies of platelet 
aggregation and platelet 
dependent thrombin 
generation   
6 ml 
(2 tubes)  
3.8% Sodium 
Citrate   
Baseline (D0) and 
end of study D28)   
NHLBI Sickle Cell 
Branch, Sickle 
Thrombosis Lab  
Leukocytes isolation for 
gene expression and RNAseq ** 
• Monocyte TF gene 
expression  
• Tissue factor RNAseq  
• Complement variants  
• P-selectin variants   
 
 
5 ml 
(1 tube)  
 
 
EDTA   
 
 
Baseline (D0) and 
end of study D28)   
 
 
NHLBI Sickle Cell 
Branch, Sickle 
Thrombosis Lab  
Contact Pathway  6 ml 
(2 tubes) 3.8% Sodium 
Citrate  + Corn 
Trypsin 
Inhibitor (CTI)   
Baseline (D0) and 
end of study D28)   
NHLBI Sickle Cell 
Branch, Sickle 
Thrombosis Lab  
41 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 8.3 S AFETY AN D OTHER ASSESSMENTS  
Physical examination , laboratory tests and adverse event review will be assessed at baseline and 
at 4 weeks.  
Safety, tolerability and adherence assessments will be performed at baseline and at 4 weeks and 
whenever clinically indicated.  
Counseling:  Subjects should maintain a stable diet and not start any new diet or active SCD 
treatment for the duration of the study. 
24-hour Dietary Recall:  At three timepoints throughout the study, trained nutrition staff from the 
NIH CC will collect a 24 -hour recall to reflect dietary intake from the prior day with nutrition 
staff entering information directly into Nutrition Data Sys tems for Research software (NDSR, 
University of Minnesota, Minneapolis, MN) to obtain nutrient and dietary quercetin intake data.  
Participants experiencing adverse events after the start of IQ/placebo up until 4 weeks after 
discontinuation, may have a clin ic visit for assessment and will be managed as clinically 
indicated. All patients will received a phone call study visit 4 weeks after IQ/placebo 
discontinuation to assess for AEs.  
 
8.4 A DVERSE EVENTS AND SERIOUS ADVERSE EVENTS  
8.4.1 Definition of Adverse Event  
Adverse event means any untoward medical occurrence associated with the use of an 
intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). 
8.4.2 Definition of Serious Adverse Events (SAE)  
An adverse event (AE) or suspected adverse reaction is considered "serious" if, in the view of the investigator, it results in any of the following outcomes: death, a life -threatening adverse event, 
inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life -threatening, 
or require hospitalization may be conside red serious when, based upon appropriate medical 
judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronc hospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse. 
8.4.3 Classification of an Adverse Event  
Severity of Event  
This study will utilize the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) for toxicity and adverse event reporting.  A copy of the CTCAE v5.0 can be downloaded from the https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
42 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 AEs will be recorded, verified, and followed until satisfactory resolution  or stabilization .  In the 
event of any treatment related  SAEs, enrollment  will be suspended until discussed with the IRB 
and Clinical Director.  
 
8.4.4 Grading and attribution of adverse events 
Severity definitions found in the CTCAE v5.0 will be used for grading the severity (intensity) of 
AEs:  
1) Mild :  Asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
2) Moderate:   Minimal, local or noninvasive intervention indicated; limiting age -appropriate 
instrumental ADL*  
3) Severe:  Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self- care 
ADL**.  
4) Life- threatening:   Life -threatening consequences; urgent intervention indicated. 
5) Death:   Death related to AE.  
 
*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the 
telephone, managing money, etc.  
**Self- care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
 
8.4.5 Relationship to Study Interventi on 
• All adverse events (AEs) must have their relationship to study intervention assessed by the investigator or designee who examines and evaluates the participant based on temporal relationship and his/her clinical judgment. The degree of certainty about causality will be graded using the categories below. In a clinical trial, the study product 
must always be suspect.  
• Definitely Related – There is clear evidence to suggest a causal relationship, and other 
possible contributing factors can be ruled out. The clinical event, including an abnormal laboratory test result, occurs in a plausible time relationship to study intervention administration and cannot be explained by concurrent disease or other drugs or chemicals. The response to withdrawal of the study i ntervention (dechallenge) should be 
clinically plausible.  
• Probably Related – There is evidence to suggest a causal relationship, and the influence of other factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs withi n a reasonable time after administration of the study intervention, is 
unlikely to be attributed to concurrent disease or other drugs or chemicals, and follows a clinically reasonable response on withdrawal (dechallenge).  
43 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 • Potentially Related – There is so me evidence to suggest a causal relationship (e.g., the 
event occurred within a reasonable time after administration of the trial medication). 
However, other factors may have contributed to the event (e.g., the participant’s clinical condition, other concomitant events). Although an AE may rate only as “possibly related” soon after discovery, it can be flagged as requiring more information and later be upgraded to “probably related” or “definitely related”, as appropriate. 
• Unlikely to be related – A clinica l event, including an abnormal laboratory test result, 
whose temporal relationship to study intervention administration makes a causal relationship improbable (e.g., the event did not occur within a reasonable time after 
administration of the study interve ntion) and in which other drugs or chemicals or 
underlying disease provides plausible explanations (e.g., the participant’s clinical 
condition, other concomitant treatments). 
• Not Related – The AE is completely independent of study intervention administration, and/or evidence exists that the event is definitely related to another etiology. There must be an alternative, definitive etiology documented by the clinician. 
 
8.4.6 Expectedness  
The PI  or designee will be responsible for determining whether an AE is expected or unexpected.  
An AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described  in the Investigator’s Brochure  for IQ .  
 We expect  some vasovagal symptoms during blood draws (expected frequency 50%) and transient 
bruising at the site of blood draws (expected frequency 50%). Approximately 20% of SCD patients 
may experience a vaso -occlusive pain crisis “acute crisis” as part of their underlying disease, 
thereby resulting in hospitalization and reporting of SAEs.  
8.4.7 Time Period and Frequency for Event Assessment and Follow -Up 
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the attention of study pers onnel during study visits and interviews of a study participant presenting 
for medical care, or upon review by a study monitor. 
Investigators will assess the occurrence of AEs and SAEs at all patient evaluation time points 
during the study.  Grade 2 and above adverse events plus grade 2 laboratory abnoramlitites associated with clinical signs or symptoms whether volunteered by the patient, discovered by study personnel during questioning, or detected through physical examination, clinically significant labo ratory test, or other means will be recorded on the appropriate CRF.Information 
to be collected includes event description, date  of onset, clinician’s assessment of severity, 
relationship to study product (assessed only by those with the training and authority to make a diagnosis), and date of resolution/stabilization of the event.AEs collected for the purpose of the study will  be documented appropriately  regardless of relationship  to the IND agent . AEs will be 
followed to adequate resolution or stabilization  or until V4 (phone call). 
The following AEs will not be captured  in the  research  database:  
• Grade 1 adverse events  
44 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 • Grade 2 laboratory abnormalities not associated with clinical signs or symptoms.   
SCD is a chronic disease associated with recurrent acute painful crises and this information  will 
be documented in the medical record.  Any medical condition that is present at the time that the 
participant is screened will be considered as baseline and not reported as an AE. However, if the 
study participant’s condition deteriorates at any time during the study, it will be recorded as an AE. Changes in the severity of an AE will be documented to allow an assessment of the duration 
of the event at each level of severity to be performed. AEs characterized as intermittent require 
documentation of onset and duration of each episode. 
The PI or designee will record all reportable events  (those entered in the research database with 
start dates occurring any time after the study intervention has started until 7 days (for non-
serious AEs or SAEs ) after the last day of administration of the study supplement. At each study 
visit, the team member will inquire about the occurrence of AE/SAEs since the last visit.  Events 
will be followed for outcome information until resolution or stabilization  or until V4 (phone 
call). 
8.4.8 Adverse Event Reporting  
  Grading and attribution of AEs captured in the database will be determined by the Principal 
Investigator or Associate Investig ator’s designated on the delegation log.   
 
8.4.9 Serious Adverse Event Reporting  
 
The study investigator will report to the sponsor any SAE  occurring after the start of 
intervention, whether or not considered study intervention related, including those listed in the 
protocol or investigator brochure and must include an assessment of whether there is a reasonable possibility that the study intervention caused the event.  
All SAEs will be followed until satisfactory resolution or until the site investigator deems the 
event to be chronic or that the participant is stable.  
The study sponsor will be responsible for notifying the Food and Drug Administration (FDA) of any unexpected fatal or life- threatening suspected adverse reaction as soon as possible, but in no 
case later than 7 calendar days after the sponsor's initial receipt of the information. In addition, the sponsor must notify FDA and all participating investigators in an Investigational New Drug (IND) safety report of potential serious  risks, from clinical trials or any other source, as soon as 
possible, but in no case later than 15 calendar days after the sponsor determines that the information qualifies for reporting  using a MedWatch Report (FDA Form 3500). 
 
Reports to the IRB and CD  
Expedited Reporting Events requiring expedited reporting will be submitted to the IRB per Policy 801 “Reporting 
Research Events”.  
 
45 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 Reports to the IRB at the time of Continuing Review:  
The PI or designee will refer to HRPP Policy 801 “Reporting Research Events” to determine 
IRB reporting requirements.  
 
Reports to the CD: 
The PI or designee will refer to NHLBI DIR Policy to determine CD reporting requirements and 
timelines.  
Reports to the DSMB  
The NHLBI DSMB as the independent data safety monitoring commit ee will review and 
approve the protocol before the enrollment.  SAEs that meet the definition of an Unanticipated Problem will be submitted to the DSMB within 7 days of the investigator being notified of the event.  DSMB will have access to safety data upo n request any time. The monitoring plan will be 
developed and approved by the DSMB before enrollment.  
 
8.4.10 Events of Special Interest  
N/A  
8.4.11 Reporting of Pregnancy  
In the event a subject becomes pregnant while on study, this event will be reported to the IRB 
and Clinical Director as a protocol deviation.  Monitoring of the pregnancy thru chart review (per HIPPA guidelines) will continue until conclusion of the pregnancy, and then subject will be taken off study. 
8.5 U
NANTICIPATED PROBLEMS  
8.5.1 Definition of Unanticipated Problems (UP) 
Any incident, experience, or outcome that meets all  of the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are described in the protocol- related documents, such as the Institutional Review 
Board (IRB) -approved research protocol and informed consent document; and (b) the 
characteristics of the participant population being studied; and  
• Related or possibly related to participation in the research (“possibly related” means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research); and 
• Suggests that the research places participants or others (which many in clude research 
staff, family members or other individuals not directly participating in the research) at a 
greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or expected . 
46 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019  8.5.2 Unanticipated Problem Reporting  
The investigator will report unanticipated problems (UPs) to the NIH Institutional Review Board 
(IRB) as per Policy 801. 
8.5.3 NIH Intramural IRB  Reporting of IND Safety Reports 
Only IND Safety Reports that meet the definit ion of an unanticipated problem will need to be 
reported to the NIH Intramural IRB . 
 
9 STATISTICAL CONSIDERATIONS  
9.1 S TATISTICAL HYPOTHESIS  
 
Treatment  with IQ  will blunt systemic inflammation and coagulation  activation in sickle cell 
disease patients . 
 
Primary Endpoint(s): The primary outcome will be the change in the plasma soluble P -selectin  
comparing the baseline to IQ  response after 28 days in patients with SCD.  
 9.2 S
AMPLE SIZE DETERMINATION  
This is a study designed to assess the effect of IQ on plasma soluble P- selectin in subjects with 
stable SCD  at baseline.  The mean baseline soluble P -selectin measurement in a cross- sectional 
study of SCD patients (n = 29) in steady state was 30 ng/ml with standard deviation of 8.4 (see 
preliminary data Figure 4). Follow- up measurements from the same individuals had mean values 
of 29 ng/ml and standard deviation of 8.4 with intra-person correlation of 0.60 for the two measurements. The proposed analysis is an analysis of covariance model with follow -up P-
selectin measurement (i.e. post -treatment measurement) as the dependent variable with baseline 
measurement and treatment assignment as the covariates. A 25 % reduction in P -selectin (i.e.  
an 7.25 ng/ml de cline from an average value of 29 ng/ml) is the hypothesized treatment effect for 
IQ proposed to achieve a clinically meaningful reduction in thrombosis risk. Under these 
conditions a total of 40 respondents (20 per arm) is needed to obtain power of 90%. Based on these considerations we request an accrual ceiling  to the study intervention portion of the study 
of 46 individuals to compensate for loss to follow -up or inaccurate sample size assumptions.  
  In the table below, we present power calculations for various scenarios. With 20 subjects on IQ  
and 20 on placebo, the study will have >90% power to detect a difference of 7.25 ng/ml in the mean baseline to 4 -week changes between the two study groups. Furt hermore, even with only 34 
subjects ( 17 in each  arm), the study will have >85% power to detect a mean change of 
7.25 ng/ml. Therefore, we request approval to enroll up to a total of 4 6 subjects to : 1) account for 
potential diluting effects of possible trea tment non -compliance , and/or study dropouts, 2) provide 
a buffer against possibly inaccurate sample size assumptions, and 3) provide power to test our hypothesis in the  subgroup of per- protocol patients who avoid crises that may distort their P -
selectin and other measurements (see section 9.3) .  
47 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019  
Table 4  
    
Analysis Method  Anticipated P -selectin 
reduction  Power  Required Sample Size 
per arm  
ANCOVA  25% 80% 15 
ANCOVA  25% 85% 17 
ANCOVA  25% 90% 20 
  
9.3 P
OPULATIONS FOR ANALYSES  
The primary analysis will be conducted among  patients with SCD that are randomized . The 
occurrence of the following clinical events that are related to the underlying disease biology may 
confound study outcomes . In particular, occurrence of acute cris es can profoundly alter 
inflammation, coagulation biology and affect P -selectin measurement. Therefore, of particular 
interest is the subgroup of steady state SCD patients that complete the 28-day study treatment 
period without experiencing an acute crisis. A subgroup analysis of the primary and key secondary endpoints will be conduct ed on this subset using the same analytic techniques.  
 
9.3.1 Evaluable for toxicity  
All patients randomized will be evaluable for toxicity from the time of their first treatment with 
study supplement  or placebo until 28 days after completion of the end of study visit . 
9.3.2 Evaluable for objective response  
N/A 
9.4 S
TATISTICAL ANALYSES  
9.4.1 General Approach 
Please refer to sections 9.4.2 , 9.4.3 and 9.4.6 for the general approach to statistical analysis.  
 
9.4.2 Analysis of the Primary Endpoints 
The primary outcome will be the change in the soluble P -selectin level comparing baseline levels 
versus their respective response to IQ or placebo among randomized SCD patients . The proposed 
statistical method  is an analysis of covariance model with follow -up P-selectin measurement (i.e. 
post- treatment measurement) as the dependent variable with baseline measurement and treatment 
assignment as the covariates. Significance in this pilot phase II study will be evaluated using a 
two-sided test with alpha level of 0.05 . 
 
48 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 9.4.3 Analysis of the Secondary Endpoint(s) 
The following endpoints are exploratory in nature: 
o Compare baseline and end of study plasma protein disulfide isomerase activity  
o Quantify baseline and end of study plasma tissue factor positive extracellular 
vesicle number  
o Compare baseline and end of study tissue factor procoagulant activity 
o Compare baseline and end of study platelet thrombin generation 
o Compare baseline and end of study inflammatory cytokines 
o Compare baseline and end of study plasma D-Dimer, TAT and PF1.2 
o Compare baseline and end of study contemporary bio markers of vascular 
endothelial function, specifically reactive hyperemia index.  
o Assess safety and tolerability of IQ  
o Assess adherence to oral IQ  
Baseline and end of study measures of secondary end points will be similarly conducted using 
ANCOVA or Wilcoxon’s rank sum test, if assumptions of normality are not warranted . We will 
explore statistical correlation between PDI activity , tissue factor EVs,  tissue factor procoagulant 
activity  and soluble P -selectin levels using Spearman’s or Pearson’s correlation coefficient s. 
Changes in hemoglobin, leukocytes, reticulocytes, platelets, LDH, Total and direct bilirubin, C-reactive protein, inflammatory cytoki ne panel and coagulation parameters from baseline after 
exposure to 28 days of Isoquercetin will be summarized. 
 
9.4.4 Safety Analyses  
The planned analyses will also include descriptive statistics on the incidence and severity of 
adverse events.  The proportions of treatment related serious adverse events (TRSAEs) will be summarized using sample proportions and confidence intervals for binomial distributions.  Safety will be summarized using descriptive statistics. Summaries will be produced for all treatment- emergent adverse events (TEAEs), related TEAEs (those considered by the 
Investigator as related to study treatment), SAEs, TEAEs leading to treatment discontinuation, and TEAEs Grade ≥3 in severity. Individual subject listings will be provided for any deaths, SAEs, TEAEs leading to interruption and TEAEs leading to treatment discontinuation.  
 Stopping rule  
When the Bayesian posterior probability reaches 75% or higher, it will trigger a meeting of the 
DMSC. The prior distribution for the probability of a qualifying adverse event is given by a beta 
distribution with parameters a = 1 .25 and b = 3.25. For stopping rule purposes, qualifying 
AEs/SAEs will only be counted in the Isoquercetin arm . Monitoring for crossing the boundary 
and reporting to the DSMB, if necessary, will be done by the unblinded statistician. 
The Table below summarizes the threshold numbers for the resulting boundary in  the 
Isoquercetin arm , which would lead to a meeting of the safety committee to evaluate stopping or 
49 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 modifying the study due to an excess number of qualifying AEs/SAEs. AEs will be counted for 
anyone randomized into the Isoquercetin arm regardless of wheth er they are withdrawn or lost to 
follow -up.  
Table  5: Threshold numbers for resulting boundary 
Number of subjects in the 
study  Hold enrollment if the number of subjects who have developed a qualifying AE/SAE is 
≤3 2 
≤7 3 
≤10 4 
≤14 5 
≤17 6 
≤21 7 
≤23 8 
 
We investigated the performance of the above stopping rule through simulation. In each 
simulation we generated a set of 23 independent Bernoulli trials; each representing an Isoquercetin- receiving  patient with  probability  p for having a qualifying AE/SAE. For each 
simulation we determined if the stopping boundary would have been reached with consideration for halting or suspending the study. We conducted this simulation 100,000 times for each different true value of probability  p and recorded the average number of Isoquercetin- receiving  
patients treated (it may be less than 23  if the study was stopped early) and the average number 
of qualifying AEs/SAEs observed. In addition, we show the proportion of the 100,000 simulations in which the stopping boundary was met. The table below summarizes the performance of the stopping rule under a number of different values for the qualifying AE/SAE probability p. 
 Table  6: Performance of the Stopping Rule under multiple scenarios for the 
qualifying AE/ SAE  Probability  p 
 
50 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 Probability of a 
qualifying AE/SAE 0.15 0.20 0.25 0.30 0.40 
Proportion of Stopped Studies 14% 28% 45% 63% 89% 
Average number of subjects 20.7 18.7 16.2 13.5 8.9 
Average number of qualifying AEs/SAEs  3.1 3.7 4.0 4.1 3.5 
 
 
9.4.5 Baseline Descriptive Statistics  
 For clinical laboratory values, and vital signs both actual values and changes from baseline will 
be summarized by visit using summary statistics.  
   
Given the short nature of the trial and safety profile of the drug, few patients are expected to drop 
out or otherwise produce missing data. Individuals with missing data will be tabulated and reasons for missing data will be collected where possible and p resented. If randomized subjects 
have missing data in either arm, then the primary analysis will employ a multiple imputation procedure that will be developed without knowledge of the treatment assignments (beyond assessing the percentage of missing outcomes in each arm). In these circumstances the analysis utilizing only available information would be secondary.   
 
10 REGULATORY AND OPERATIONAL CONSIDERATIONS  
10.1 I
NFORMED CONSENT PROCESS  
10.1.1 Consent /Assent  Procedures and Documentation 
Informed consent will be conducted following OHSRP Policy 301- Informed Consent. 
An IRB-approved consent form will be provided to the participant electronically or by hard copy for review prior to consenting. The initial conse nt process as well as re- consent, when required,  
may take place in person or remotely (e.g., via telephone or other NIH approved platforms). The investigational nature and objectives of this trial, the procedures, and their attendant risks and discomforts and potential benefits will be carefully explained to the participant in a private setting. The participant will be given as much time as they need to review the document and to consult with their family, friends, and personal health care providers. In addition, a study team member 
51 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 will be available to answer any questions.  
A signed and dated informed consent document will be obtained by any investigator authorized 
to consent (See Key Study Personnel Page) prior to entry onto the study. Consent may be 
obtained with required signatures on the hard copy of the consent or on the electronic document. 
When a document that is in electronic format is used for obtaining consent, this study may use 
the iMed platform which is 21 CFR, Part 11 compliant, to obtain the required signatures. During the consent process, participants and investigators may view the same approved consent document simultaneously when participant is being consented in person at the Clinical Center or both may view individual copies of the approved consent document on screens in their respective locations remotely. Signatures may be obtained either by both directly signing on the device that the consenting investigator is using (when in person) or through iMed Mobile Signature Capture (remotely) wh ich allows texting or emailing a link to the participant. That link allows the  
participant to review the consent, then proceed to sign on the device they are using. Whether hard copy or electronic, both the investigator and the participant will sign the document  
with a hand signature using a pen (if using hard copy), finger, stylus, or mouse (if electronic). When done remotely, if the participant prefers to sign a hard copy, they may be instructed to sign and date the consent document during the discussion and mail, secure email or fax the signed document to the consenting investigator. Whether in person or remotely, the privacy of the participant will be maintained. Finally, the fully signed informed consent document will be stored  in the electro nic medical record, and the participant will receive a copy of the signed 
informed  
consent document. 
 
10.1.2 Consent for minors when they reach the age of majority  
N/A 
10.1.3 Telephone consent  
N/A 
10.1.4 Participation of Subjects who are/become Decisionally Impaired  
N/A 10.2 S
TUDY DISCONTINUATION AND CLOSURE  
 This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause.  If the study is prematurely terminated or suspended, the Principal Investigator (PI) will promptly inform study participants, the Institutional Review Board (IRB), and will provide the reason(s) for the termination or suspension.  Study participants will be contacted, as applicable, and be informed of changes to study visit schedule. 
 Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants 
• Insufficient compliance to protocol requirements  
52 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 • Data that are not sufficiently complete  and/or evaluable  
Study may resume once concerns about safety, protocol compliance, and data quality are 
addressed, and satisfy the IRB. 
10.3 C ONFIDENTIALITY AND PRIVACY  
Participant confidentiality and privacy is strictly held in trust by the participating  investigators, 
their staff. This confidentiality is extended to cover testing of biological samples in addition to 
the clinical information relating to participants. Therefore, the study protocol, documentation, 
data, and all other information generated w ill be held in strict confidence.  
All research activities will be conducted in as private a setting as possible.  
The study monitor, other authorized representatives of the sponsor, representatives of the Institutional Review Board (IRB), and/or regulatory agencies may inspect all documents and records required to be maintained by the investigator, including but not l imited to, medical 
records (office, clinic, or hospital) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
The study participant’s contact information will be securely stored at the NIH  for internal use 
during the study. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by the reviewing IRB, Institutional policies, or sponsor requirements.  
Study participant research data, whic h is for purposes of statistical analysis and scientific 
reporting, will be  stored in a research database in conformity with NHLBI DIR policy . Individual 
participants and their research data will be identified by a unique study identification number. The s tudy data entry and study management systems used by clinical sites and by  the research 
staff will be secured and password protected.  
To further protect the privacy of study participants, a Certificate of Confidentiality has been 
issued by the National Institutes of Health (NIH).  This certificate protects identifiable research information from forced disclosure. It allows the investigator and others who have access to research records to refuse to disclose identifying information on research participation in any civil, criminal, administrative, legislative, or other proceeding, whether at the federal, state, or local level. By protecting researchers and institutions from being compelled to disclose information that would identify research participants, Cer tificates of Confidentiality help achieve 
the research objectives and promote participation in studies by helping assure confidentiality and privacy to participants.  
10.4 F
UTURE USE OF STORED SPECIMENS AND DATA 
We may share specimens and data with other researchers for future use.  
Following analyses of biospecimens for primary research purposes as described in the protocol, remaining samples suitable for future research will be stored in manner that conforms with DIR policy (such as BSI) or in a publicly ac cessible research biospecimen repository following IRB 
approval.  Biospecimens may be destroyed only when permitted by the clinical director and approved by the IRB.  Any future research use of identifiable biospecimens not defined in the 
research protocol will occur only after IRB review and approval. 
53 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019  
10.5 S AFETY OVERSIGHT  
Safety oversight will be under the direction of a DSMB composed of individuals with the 
appropriate expertise . Members of the DSMB should be independent from the study conduct and 
free of conflict of interest, or measures should be in place to minimize perceived conflict of interest.  The DSMB will meet semiannually  or annually to assess safety and efficacy data on 
each arm of the study. The DMSB will operate under the rules of an approved charter that will be written and reviewed at the organizational meeting of the DSMB. At this time, each data element that the DSMB needs to assess will be clearly defined. The DSMB will provide its input to National Institutes of Health staff.  
10.6 C
LINICAL MONITORING  
The monitoring of  this study will be conducted by clinical research  associates (CRAs)/ monitors 
employed by an independent contract organization working under an agreement with NHLBI to monitor aspects of the study in accordance with  the appropriate regulations and the approved 
protocol. The objectives of a monitoring visit will be: 1) to verify the existence of signed informed consent form (ICF) and documentation of the ICF process for each monitored subject; 2) to verify the prompt and accurate recording of all monitored data points, and prompt reporting of all SAEs; 3) to compare abstracted information with individual subjects’ records and source documents (subject’s charts, laboratory analyses and test results, physicians’ progress  notes, nurses’ notes, 
and any other relevant original subject information); and 4) to help ensure investigators are in compliance with the protocol. The monitors also will inspect the clinical site regulatory files to ensure that regulatory requirements (Office for Human Research Protections -OHRP) and 
applicable guidelines (ICH -GCP) are being followed.  Monitoring will be conducted according to 
the OCD schedule.  During the monitoring visits, the investigator (and/or designee) and other study personnel will be available to discuss the study progress and monitoring visit. 
The investigator (and/or designee) will make study documents (e.g., consent forms and pertinent 
hospital or clinical records readily available for inspection by the local IRB, the site monitors, and the NHLBI staff for confirmation of the study data.  
10.7 Q
UALITY ASSURANCE AND QUALITY CONTROL  
Quality control (Q C) procedures will be implemented beginning with the data entry system and 
data QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s)  for clarification/resolution.  
Following written Standard Operating Procedures (SOPs) , the monitors will verify that the 
clinical trial is conducted and data are generated  and biological specimens are collected , 
documented (recorded), and reported in compliance with the protocol, International Conference on Harmonization  Good Clinical Practice (ICH GCP ), and applicable regulatory requirements 
(e.g., Good Laboratory Practices ( GLP ), Good Manufacturing Practices ( GMP )).  
The investigational site will provide direct access to all trial related sites, source data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory author ities.  
 
54 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 10.8 D ATA HANDLING AND RECORD KEEPING  
 10.8.1 Data Collection  and Management Responsibilities 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site investigator. The invest igator is responsible for ensuring the accuracy, completeness, 
legibility, and timeliness of the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.   
Data recorded in the electronic case report form (eCRF) derived from source documents should be consistent with the data recorded on the source documents.  
Clinical data and clinical laboratory data will be entered into CTDB, a 21 CFR Part 11- compliant 
data capture system. Clinical data will be entered directly from the source documents.  
10.8.2 Study Records Retention 
Study documents should be retained for a minimum of 2 years after the last approval of a 
marketing application in an  International Conference on Harmonization  (ICH) region and until 
there are no pending or contemplated marketing applications in an ICH region or until at least 2 years have elapsed since the formal discontinuation of clinical development of the study intervention, or as per the NIH Intramural Records Retention Schedule. No records will be 
destroyed without the written consent of the NHLBI Clinical Director.  
 10.9 P
ROTOCOL DEVIATIONS  
It is the responsibility of the investigator to use continuous vigilance to identify and report 
deviations to the NIH Institutional Review Board as per Policy 801.   
NIH Definition of Protocol Deviation  
A protocol deviation is any changed, divergence, or departure from the IRB -approved research 
protocol.  
• Major deviations: Deviations from the IRB approved protocol that have, or may have the 
potential to, negatively impact the rights, welfare or safety of the subject, or to 
substantially negatively impact the scientific integrity or validity of the study.  
• Minor deviations: Deviations that do not have the potential to negatively impact the rights, safety or welfare of subjects or others, or the scientific integrity or validity of the study. 
10.10 P
UBLICATION A ND DATA SHARING POLICY  
10.10.1 Human Data Sharing Plan 
This study will be conducted in accordance with the following publication and data sharing policies and regulations:  
National Institutes of Health (NIH) Public Access Policy, which ensures that the pub lic has 
access to the published results of NIH funded research. It requires scientists to submit final peer -
55 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central 
upon acceptance for publication. 
This study will comply  with the NIH Data Sharing Policy and Policy on the Dissemination of 
NIH- Funded Clinical Trial Information and the Clinical Trials Registration and Results 
Information Submission rule. As such, this trial will be registered at ClinicalTrials.gov, and 
resul ts information from this trial will be submitted to ClinicalTrials.gov. In addition, every 
attempt will be made to publish results in peer -reviewed journals.  Data from this study may be 
requested from other researchers 3 years after the completion of the primary endpoint by contacting Dr. Arun Shet at the NHLBI  
 
10.10.2 Genomic Data Sharing Plan 
N/A 
10.11 C
OLLABORATIVE AGREEMENTS  
 
10.11.1 Agreement Type 
A Clinical Material Supply Agreement between NHLBI and Querces AG  for the conduct of this 
study is being executed.  10.12 C
ONFLICT OF INTEREST POLICY  
The independence of this study from any actual or perceived influence, such as by the 
pharmaceutical industry, is critical.  Therefore, any actual conflict of interest of persons who 
have a role in the des ign, conduct, analysis, publication, or any aspect of this trial will be 
disclosed and managed. Furthermore, persons who have a perceived conflict of interest will be 
required to have such conflicts managed in a way that is appropriate to their participation in the design and conduct of this trial.  The study leadership in conjunction with the NHLBI  has 
established policies and procedures for all study group members to disclose all conflicts of interest and will establish a mechanism for the management of all reported dualities of interest.  
 
11 ABBREVIATIONS  
 
ACS   
Acute Chest Syndrome  
ADME  Absorption, Distribution, Metabolism, and Elimination  
AE Adverse Event  
AT Anti-Thrombin  
BAUS  Brachial Artery Ultrasound  
BNP  B-type natriuretic peptide  
CFR  Code of Federal Regulations  
CLIA  Clinical Laboratory Improvement Amendments  
COC  Certificate of Confidentiality  
56 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 CRF  Case Report Form  
CRP  C-Reactive Protein  
CTCAE  Common Terminology Criteria for Adverse Events  
CTEPH  chronic thromboembolic pulmonary hypertension  
DHHS  Department of Health and Human Services  
DSMB  Data Safety Monitoring Board  
DSMB  Data Safety Monitoring Board  
DSMC  Data Safety and Monitoring Committee  
DVT  Deep Venous Thrombosis  
eCRF  Electronic Case Report Forms  
ELISA  Enzyme -Linked Immunosorbent Assay  
EOS  End of Study  
ER Endoplasmic Reticulum  
EVs Extracellular Vesicles  
FDA  Food and Drug Administration  
FDAAA  Food and Drug Administration Amendments Act of 2007  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practices  
GMP  Good Manufacturing Practices  
GRAS  Generally Recognized As Safe  
HbS Hemoglobin S  
HCG  Human Chorionic Gonadotrophins  
HCV  Hepatitis C Virus 
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
HMGB1  h\High Mobility Broup Box-1 
HU Hydroxy Urea  
ICH International Conference on Harmonization  
IND Investigational New Drug Application  
IND Investigational New Drug  
IQ Isoquercetin  
IRB Institutional Review Board  
MAS  Medical Administrative Series  
NCT  National Clinical Trial  
NHLBI  National Heart, Lung and Blood Institute  
NIH  National Institutes of Health  
NIH IC  NIH Institute or Center  
NIRS  Near Infrared Spectroscopy  
NO Nitric Oxide 
NTP  National Toxicology Program  
OHRP  Office for Human Research Protections  
PAT  Peripheral Arterial Tonometry  
PDI protein disulfide isomerase  
PI Principal Investigator  
PRO  Patient Recruitment Office  
PTT Partial Thromboplastin Time  
QA Quality Assurance  
QC Quality Control  
RBC  Red Blood Cell  
SAE  Serious Adverse Event  
SAE  Serious Adverse Event  
SCD  Sickle Cell Disease  
57 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 SOA  Schedule of Activities  
SOC  System Organ Class  
SOP Standard Operating Procedure  
SOPs  Standard Operating Procedures  
TAT  Thrombin -Antithrombin Complexes  
TEAEs  Treatment -Emergent Adverse Events  
TF Tissue Factor  
TLR4  Toll Like Receptor 4  
UP Unanticipated Problem  
US United States  
VOC  Vaso-Occlusive Crises 
VTE  Venous Thromboembolism  
vWF  von Willebrand Factor  
 
  
58 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 REFERENCES  
 
1. Shet AS, Wun T. How I diagnose and treat venous thromboembolism in sickle cell 
disease. Blood  2018; 132(17): 1761-9. 
2. Brunson A, Keegan T, Mahajan A, White R, Wun T. High Incidence of Venous Thromboembolism Recurrence in Patients with Sickle Cell Disease. Am J Hematol  2019. 
3. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous T hromboembolism. N Engl J Med 2018; 378(7): 615-24. 
4. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the Prevention of Pain Crises in 
Sickle Cell Disease. N Engl J Med 2017; 376(5): 429 -39. 
5. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest  1998; 101(9): 1899-904. 
6. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997; 337 (22): 1584-90. 
7. Prado GN, Romero JR, Rivera A. Endothelin- 1 receptor antagonists regulate cell surface -
associated protein disulfide isomerase in sickle cell disease. FASEB J  2013; 27(11): 4619-29. 
8. Global, regional, and national age- sex specific all -cause and cause- specif ic mortality for 
240 causes of death, 1990- 2013: a systematic analysis for the Global Burden of Disease Study 
2013. Lancet  2015; 385(9963): 117-71. 
9. Stopa JD, Neuberg D, Puligandla M, Furie B, Flaumenhaft R, Zwicker JI. Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. JCI Insight  2017; 2(1): e89373. 
10. Jasuja R, Furie B, Furie BC. Endothelium-derived but not platelet-derived protein disulfide isomerase is required for thrombus formation in vivo. Blood 2010; 116(22): 4665-74. 
11. Ahamed J, Versteeg HH, Kerver M, et al. Disulfide isomerization switches tissue factor 
from coagulation to cell signaling. Proc Natl Acad Sci U S A  2006; 103(38): 13932-7. 
12. Reinhardt C, von Bruhl ML, M anukyan D, et al. Protein disulfide isomerase acts as an 
injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest  
2008; 118(3): 1110-22. 13. Fang C, Sharda A, Lin L, Flaumenhaft R, Furie B. Inhibition of Protein Disulfide 
Isomerase Ameliorates Vaso -Occlusion and Thrombosis in a Mouse Model of Sickle Cell 
Disease. Blood 2017 30: 442. 
14. Zwicker JI, Schlechter BL, Stopa JD, et al. Targeting protein disulfide isomerase with the 
flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight 2019; 4(4).  
15. Williams TN, Thein SL. Sickle Cell Anemia and Its Phenotypes. Annu Rev Genomics 
Hum Genet  2018; 19: 113 -47. 
59 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 16. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in 
neonates: a contemporary geostatistical model -based map and population estimates. Lancet  
2013; 381(9861): 142- 51. 
17. Piel FB, Tatem AJ, Huang Z, Gupta S, Williams TN, Weather all DJ. Global migration 
and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends 
between 1960 and 2000. Lancet Glob Health 2014; 2(2): e80-9. 
18. Thornburg CD, Ware RE. Children with sickle cell disease migrating to the  United States 
from sub -Saharan Africa. Pediatr Blood Cancer  2018; 65(6): e27000. 
19. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med  2010; 
38(4 Suppl): S512-21. 20. Ojodu J, Hulihan M, Pope S, Grant A. Incidence of Sickle Cell Trait — United States, 
2010, 2014. 21. Carroll CP, Haywood C, Jr., Fagan P, Lanzkron S. The course and correlates of high 
hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization. Am J Hematol  2009; 84 (10): 666- 70. 
22. Thein SL, Howard J. How I treat the older adult with sickle cell disease. Blood 2018; 
132(17): 1750-60. 
23. van Tuijn CFJ, Schimmel M, van Beers EJ, Nur E, Biemond BJ. Prospective evaluation 
of chronic organ damage in adult sickle cell patients: A seven -year follow -up study. Am J 
Hematol  2017; 92(10): E584-E90. 
24. Knight- Madden JM, Barton -Gooden A, Weaver SR, Reid M, Greenough A. Mortality, 
asthma, smoking and acute chest syndrome in young adults with sickle cell disease. Lung  2013; 
191(1): 95 -100. 
25. Allareddy V, Roy A, Lee MK, et al. Outcomes of acute chest syndrome in adult patients with sickle cell disease: predictors of mortality. PLoS One  2014; 9(4): e94387. 
26. Brunson A, Lei A, Rosenberg AS, White RH, Keegan T, Wun T. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. Br J Haematol  2017; 178(2): 319-26. 
27. Gladwin MT, Barst RJ, Gibbs JS, et al. Risk factors for death in 632 patients with sickle 
cell disease in the United States and United Kingdom. PLoS One  2014; 9(7): e99489. 
28. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350(9): 886-95. 
29. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle 
cell disease and pulmonary hypertension. JAMA 2012; 307(12): 1254-6. 
30. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in 
sickle cell disease. N Engl J Med 2011; 365(1): 44-53. 
31. Naik RP, Streiff MB, Haywood C, Jr., Segal JB, Lanzkron S. Venous thromboembolism 
incidence in the Cooperative Study of Sickle Cell Disease. J Thromb Haemost  2014; 12(12): 
2010-6. 
60 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 32. Adedeji MO, Cespedes J, Allen K, Subramony C, Hughson MD. Pulmonary thro mbotic 
arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 2001; 125(11): 1436-41. 
33. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of 
hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 
17-year, single- center trial (LaSHS). Blood 2010; 115(12): 2354-63. 
34. Le PQ, Gulbis B, Dedeken L, et al. Survival among children and adults with sickle cell 
disease in Belgium: Benefit from hydroxyurea treatment. Pedi atr Blood Cancer  2015; 62(11): 
1956-61. 
35. Tisdale J. Improvements in haploidentical transplantation for sickle cell disease and beta-
thalassaemia. Lancet Haematol  2019; 6(4): e168-e9. 
36. Shet AS, Thein SL. A Growing Population of Older Adults with Sickl e Cell Disease. Clin 
Geriatr Med  2019; 35(3): 349-67. 
37. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet  1999; 353 (9159): 1167-
73. 38. Folsom AR, Tang W, Roetker NS, et al. Prospective study of sickle cell trait and venous 
thromboembolism incidence. J Thromb Haemost  2015; 13(1): 2 -9. 
39. Little I, Vinogradova Y, Orton E, Kai J, Qureshi N. Venous thromboembolism in adults screened for sickle cell trait: a population -based cohort study with nested case-control analysis. 
BMJ Open  2017; 7(3): e0 12665. 
40. White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128(9): 737-40. 
41. Ohene- Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle 
cell disease: rates and risk factors. Blood 1998; 91(1): 288- 94. 
42. Tuohy AM, McKie V, Manci EA, Adams RJ. Internal carotid artery occlusion in a child 
with sickle cell disease: case report and immunohistochemical study. J Pediatr Hematol Oncol  
1997; 19(5): 455-8. 
43. Ogunsile FJ, Naik R, Lanzkron S. Overcoming challenges of venous thromboembolism 
in sickle cell disease treatment. Expert Rev Hematol  2019; 12 (3): 173-82. 
44. Wolberg AS, Rosendaal FR, Weitz JI, et al. Venous thrombosis. Nat Rev Dis Primers 2015; 1: 15006. 
45. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol  2015; 12(8): 464-
74. 46. Villanueva H, Kuril S, Krajewski J, Sedrak A. Pulmonary thromboembolism in a child 
with sickle cell hemoglobin d disease in the setting of acute chest syndrome. Case Rep Pediatr  
2013; 2013: 875683. 
47. Lee AY, Levine MN, Baker RI, et al. Low- molecular -weig ht heparin versus a coumarin 
for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med  
2003; 349(2): 146 -53. 
61 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 48. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST 
Guideline and Expert Panel Report. Chest  2016; 149(2): 315-52. 
49. Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and 
pulmonary embolism. Blood 2014; 123(12): 1794-801. 
50. Buller HR, Gailani D, Weitz JI. Factor XI antisense oligonucleotide for venous 
thrombosis. N Engl J Med 2015; 372(17): 1672. 
51. Embury S.H HRP, Steinberg M.H., Mohandas N. Pathogenesis of vasooclusion. In: 
Embury S.H HRP, Steinberg M.H., Mohandas N., ed. Sickle Disease: Basic Principles and Clinical Practice. New York: Raven Press,L td; 1994: 311- 26. 
52. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337(11): 
762-9. 
53. Hebbel RP, Moldow CF, Steinberg MH. Modulation of erythrocyte-endothelial 
interactions and the vasocclusive severity of sickling disord ers. Blood 1981; 58(5): 947-52. 
54. Hebbel RP, Boogaerts MA, Koresawa S, Jacob HS, Eaton JW, Steinberg MH. Erytrocyte adherence to endothelium as a determinant of vasocclusive severity in sickle cell disease. Trans Assoc Am Physicians 1980; 93: 94- 9. 
55. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol  2009; 84(9): 618-25. 
56. Bunn HF, Forget BG, editors. Hemoglobin: Molecular, Genetic, and Clinical Aspects. Philadelphia: W.B. Saunders; 1986. 
57. Allan D, Limbrick AR, Thomas P, Westerman MP. Release of spectrin -free spicules on 
reoxygenation of sickled erythrocytes. Nature  1982; 295(5850): 612-3. 
58. Camus SM, De Moraes JA, Bonnin P, et al. Circulating cell membrane microparticles 
transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood  2015; 
125(24): 3805-14. 59. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in 
transgenic sickle mice but not in normal mice. J Clin Invest  2000; 106(3): 411-20. 
60. Hebbel RP. Ischemia -reperfusion injury in sickle cell anemia: relationship to acute chest 
syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematol Oncol Clin North Am  2014; 28(2): 181-98. 
61. Ansari J, Gavins FNE. Ischemia- Reperfusion Injury in Sickle Cell Disease: From Basics 
to Therapeutics. Am J Pathol  2019; 189 (4): 706- 18. 
62. Reiter CD, Wang X, Tanus- Santos JE, et al. Cell -free hemoglobin limits nitric oxide 
bioavailability in sickle- cell disease. Nat Med  2002; 8(12): 1383-9. 
63. Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothel ial cell activation and vaso -occlusion in murine sickle cell disease. Blood 2014; 123(3): 
377-90. 
62 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 64. Setty BN, Betal SG, Zhang J, Stuart MJ. Heme induces endothelial tissue factor 
expression: potential role in hemostatic activation in patients with hemoly tic anemia. J Thromb 
Haemost  2008; 6(12): 2202-9. 
65. Lv B, Wang H, Tang Y, Fan Z, Xiao X, Chen F. High-mobility group box 1 protein 
induces tissue factor expression in vascular endothelial cells via activation of NF -kappaB and 
Egr-1. Thromb Haemost  2009; 102(2): 352 -9. 
66. Xu H, Wandersee NJ, Guo Y, et al. Sickle cell disease increases high mobility group box 1: a novel mechanism of inflammation. Blood 2014; 124(26): 3978-81. 
67. Stark K, Philippi V, Stockhausen S, et al. Disulfide HMGB1 derived from plate lets 
coordinates venous thrombosis in mice. Blood 2016; 128(20): 2435-49. 
68. Vogel S, Arora T, Wang X, et al. The platelet NLRP3 inflammasome is upregulated in 
sickle cell disease via HMGB1/TLR4 and Bruton tyrosine kinase. Blood Adv  2018; 2 (20): 2672-
80. 69. Chen G, Zhang D, Fuchs TA, Manwani D, Wagner DD, Frenette PS. Heme-induced 
neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood  2014; 
123(24): 3818-27. 
70. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. 
Proc Natl Acad Sci U S A  2010; 107(36): 15880-5. 
71. Wang X, Mendelsohn L, Rogers H, et al. Heme-bound iron activates placenta growth 
factor in erythroid cells via erythroid Kruppel-like factor. Blood 2014; 124(6): 946- 54. 
72. Kalra VK, Zhang S, Malik P, Tahara SM. Placenta growth factor mediated gene regulation in sickle cell disease. Blood Rev  2018; 32(1): 61 -70. 
73. Faes C, Ilich A, Sotiaux A, et al. Red blood cells modulate structure and dynamics of venous clot formation in s ickle cell disease. Blood  2019; 133(23): 2529- 41. 
74. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91(10): 3527-61. 
75. Green D, Scott JP. Is sickle cell crisis a thrombotic event? Am J Hematol  1986; 23(4): 
317-21. 76. Franc is RB. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible 
role in vascular occlusion. Blood Coagul Fibrinolysis  1991; 2 (2): 341-53. 
77. Ataga KI, Brittain JE, Desai P, et al. Association of coagulation activation with clinical 
complications in sickle cell disease. PLoS One  2012; 7(1): e29786. 
78. Pakbaz Z, Wun T. Role of the hemostatic system on sickle cell disease pathophysiology 
and potential therapeutics. Hematol Oncol Clin North Am  2014; 28(2): 355-74. 
79. Noubouossie D, Key NS, Ataga KI. Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev  
2016; 30(4): 245-56. 
63 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 80. Grover SP, Mackman N. Tissue Factor: An Essential Mediator of Hemostasis and Trigger 
of Thrombosis. Arterioscler Thromb Vasc Biol  2018; 38(4): 709-25. 
81. Shet AS, Aras O, Gupta K, et al. Sickle blood contains tissue factor-positive 
microparticles derived from endothelial cells and monocytes. Blood 2003; 102(7): 2678-83. 
82. Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity 
is elevated in patients with sickle cell disease. Blood  1998; 91(11): 4216- 23. 
83. Setty BN, Key NS, Rao AK, et al. Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis. Br J Haematol  2012; 157 (3): 370-
80. 
84. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell 
connection. Blood 2001; 98(12): 3228-33. 
85. Osarogiagbon UR, Choong S, Belc her JD, Vercellotti GM, Paller MS, Hebbel RP. 
Reperfusion injury pathophysiology in sickle transgenic mice. Blood 2000; 96(1): 314-20. 86. Kaul DK, Chen D, Zhan J. Adhesion of sickle cells to vascular endothelium is critically 
dependent on changes in densi ty and shape of the cells. Blood 1994; 83(10): 3006-17. 
87. Kaul DK, Liu XD, Choong S, Belcher JD, Vercellotti GM, Hebbel RP. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol  2004; 287(1): H293-301. 
88. Hebbel RP, Vercellotti GM, Pace BS, et al. The HDAC inhibitors trichostatin A and 
suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic m ice. Blood 2010; 115(12): 2483-90. 
89. Turhan A, Jenab P, Bruhns P, Ravetch JV, Coller BS, Frenette PS. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Bloo d 2004; 103(6): 2397-
400. 
90. Chang J, Shi PA, Chiang EY, Frenette PS. Intravenous immunoglobulins reverse acute 
vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 
2008; 111(2): 915 -23. 
91. Arumugam PI, Mullins  ES, Shanmukhappa SK, et al. Genetic diminution of circulating 
prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. Blood 2015; 
126(15): 1844-55. 
92. Gavins FN, Russell J, Senchenkova EL, et al. Mechanisms of enhanced thrombus 
formation in cerebral microvessels of mice expressing hemoglobin -S. Blood  2011; 117(15): 
4125-33. 
93. Chantrathammachart P, Mackman N, Sparkenbaugh E, et al. Tissue factor promotes 
activation of coagulation and inflammation in a mouse model of sickle cell diseas e. Blood 2012; 
120(3): 636-46. 
64 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 94. Sparkenbaugh EM, Chantrathammachart P, Chandarajoti K, Mackman N, Key NS, 
Pawlinski R. Thrombin -independent contribution of tissue factor to inflammation and cardiac 
hypertrophy in a mouse model of sickle cell disease. Bl ood 2016; 127(10): 1371-3. 
95. Solovey A, Kollander R, Shet A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004; 104(3): 840-6. 
96. Sundd P, Gladwin MT, Novelli EM. Pathophysiology of Sickle Cell Disease. Annu Rev 
Pathol  2019; 14: 263- 92. 
97. Lawson CA, Yan SD, Yan SF, et al. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest 1997; 99(7): 1729-38. 
98. Yan SF, Zou YS, Gao Y, et al. Tissue factor transcription driven by Egr- 1 is a critical 
mechan ism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci U S A  1998; 
95(14): 8298-303. 99. Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH. P- selectin mediates 
the adhesion of sickle erythrocytes to the endothelium. Blood  2001; 98(6): 1955-62. 
100. Matsui NM, Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood 
cells to P -selectin. Blood 2002; 100(10): 3790-6. 
101. Embury SH, Matsui NM, Ramanujam S, et al. The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood 2004; 104 (10): 
3378-85. 
102. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary rol e for adherent 
leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A  2002; 
99(5): 3047-51. 103. Wood KC, Hebbel RP, Granger DN. Endothelial Cell P- selectin Mediates a 
Proinflammatory and Prothrombogenic Phenotype in Cerebra l Venules of Sickle Cell Transgenic 
Mice. Am J Physiol Heart Circ Physiol  2004. 
104. Frenette PS. Sickle cell vaso -occlusion: multistep and multicellular paradigm. Curr Opin 
Hematol  2002; 9(2): 101-6. 
105. Gutsaeva DR, Parkerson JB, Yerigenahally SD, et al . Inhibition of cell adhesion by anti-
P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood 2011; 117(2): 
727-35. 106. Merle NS, Paule R, Leon J, et al. P -selectin drives complement attack on endothelium 
during intravascular hemolysis in TLR-4/heme- dependent manner. Proc Natl Acad Sci U S A  
2019; 116(13): 6280-5. 107. van Es N, Louzada M, Carrier M, et al. Predicting the risk of recurrent venous 
thromboembolism in patients with cancer: A prospective cohort study. Thromb Res  2018; 163: 
41-6. 
65 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 108. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P- selectin are 
predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and 
Thrombosis Study (CATS). Blood 2008; 112(7): 2703-8. 
109. Panicker SR, Mehta-D'souza P, Zhang N, Klopocki AG, Shao B, McEver RP. Circulating 
soluble P- selectin must dimerize to promote inflammation and coagulation in mice. Blood 2017; 
130(2): 181-91. 
110. Mohan JS, Lip GY, Bareford D, Blann AD. Platelet P- selectin an d platelet mass, volume 
and component in sickle cell disease: Relationship to genotype. Thromb Res  2005. 
111. Connes P, Alexy T, Detterich J, Romana M, Hardy- Dessources MD, Ballas SK. The role 
of blood rheology in sickle cell disease. Blood Rev  2016; 30(2) : 111-8. 
112. Polanowska- Grabowska R, Wallace K, Field JJ, et al. P -selectin -mediated platelet -
neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. 
Arterioscler Thromb Vasc Biol  2010; 30(12): 2392-9. 
113. Mackman N. Regulation of the tissue factor gene. Thromb Haemost  1997; 78(1): 747- 54. 
114. Ansari SA, Pendurthi UR, Rao LVM. Role of Cell Surface Lipids and Thiol-Disulphide Exchange Pathways in Regulating the Encryption and Decryption of Tissue Factor. Thromb 
Haemost  2019; 119(6): 860-70. 
115. Date K, Ettelaie C, Maraveyas A. Tissue factor -bearing microparticles and inflammation: 
a potential mechanism for the development of venous thromboembolism in cancer. J Thromb Haemost  2017; 15(12): 2289-99. 
116. Aras O, Shet A, Bach RR, et al. Induction of microparticle - and cell -associated 
intravascular t issue factor in human endotoxemia. Blood 2004; 103(12): 4545-53. 
117. Butenas S, Bouchard BA, Brummel- Ziedins KE, Parhami -Seren B, Mann KG. Tissue 
factor activity in whole blood. Blood 2005; 105(7): 2764-70. 
118. Langer F, Ruf W. Synergies of phosphatidylserine and protein disulfide isomerase in 
tissue factor activation. Thromb Haemost  2014; 111(4): 590-7. 
119. Versteeg HH, Ruf W. Thiol pathways in the regulation of tissue factor prothrombotic activity. Curr Opin Hematol  2011; 18 (5): 343-8. 
120. Bach R, Gen try R, Nemerson Y. Factor VII binding to tissue factor in reconstituted 
phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25(14): 4007-20. 
121. Chen VM, Ahamed J, Versteeg HH, Berndt MC, Ruf W, Hogg PJ. Evidence fo r 
activation of tissue factor by an allosteric disulfide bond. Biochemistry 2006; 45(39): 12020-8. 122. Ruf W, Versteeg HH. Tissue factor mutated at the allosteric Cys186 -Cys209 disulfide 
bond is severely impaired in decrypted procoagulant activity. Blood 2010; 116(3): 500-1; author 
reply 2-3. 
123. Krudysz-Amblo J, Jennings ME, 2nd, Knight T, Matthews DE, Mann KG, Butenas S. 
Disulfide reduction abolishes tissue factor cofactor function. Biochim Biophys Acta 2013; 
1830(6): 3489-96. 
66 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019 124. Rao LV, Kothari H, Pe ndurthi UR. Tissue factor: mechanisms of decryption. Front 
Biosci (Elite Ed) 2012; 4 : 1513-27. 
125. Flaumenhaft R, Furie B. Vascular thiol isomerases. Blood 2016; 128(7): 893-901. 
126. Cho J, Furie BC, Coughlin SR, Furie B. A critical role for extracellular protein disulfide 
isomerase during thrombus formation in mice. J Clin Invest  2008; 118(3): 1123-31. 
127. Essex DW, Wu Y. Multiple protein disulfide isomerases support thrombosis. Curr  Opin 
Hematol  2018; 25(5): 395-402. 
128. Bekendam RH, Iyu D, Passam F, et al. Protein disulfide isomerase regulation by nitric 
oxide maintains vascular quiescence and controls thrombus formation. J Thromb Haemost  2018; 
16(11): 2322-35. 
129. Essex DW, Miller A, Swiatkowska M, Feinman RD. Protein disulfide isomerase 
catalyzes the formation of disulfide -linked complexes of vitronectin with thrombin -antithrombin. 
Biochemistry 1999; 38(32): 10398-405. 130. Oliveira PVS, Garcia -Rosa S, Sachetto ATA , et al. Protein disulfide isomerase plasma 
levels in healthy humans reveal proteomic signatures involved in contrasting endothelial 
phenotypes. Redox Biol  2019; 22: 101142. 
131. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet  1993; 
342(8878): 1007-11. 
132. Lin L, Gopal S, Sharda A, et al. Quercetin-3- rutinoside Inhibits Protein Disulfide 
Isomerase by Binding to Its b'x Domain. J Biol Chem  2015; 290(39): 23543-52. 
133. Hollman PC, de Vries JH, van Leeuwen SD, Mengelers MJ, Katan MB. Absorption of 
dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr  1995; 
62(6): 1276-82. 
134. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and 
bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr  
2005; 81(1 Suppl): 230S -42S. 
135. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab 
Clin Med  2001; 137(6): 398-407. 
136. Wun T, Paglieroni T, Rangaswami A, et al. Platelet activation in patients with sickle cell disease. Br J Haematol  1998; 100(4): 741-9. 
137. National Toxicology P. Toxicology and Carcinogenesis Studies of Quercetin (CAS No. 117-39-5) in F344 Rats (Feed Studies). Natl Toxicol Program Tech Rep Ser  1992; 409 : 1-171. 
138. Cialdella -Kam L, Nieman DC, Sha W, Meaney MP, Knab AM, Shanely RA. Dose-
response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults. Br J Nutr 2013; 109 (11): 1923- 33. 
139. Charache S, Terrin ML, Moore RD , et al. Effect of hydroxyurea on the frequency of 
painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332(20): 1317-22. 
67 
Abbreviated Title:  IQ in sickle cell disease  
Version Date : May 5, 2023 
 
Template version date 07 -29-2019  